US20100075295A1 - Novel Cellular Compositions and Methods for Their Preparation - Google Patents
Novel Cellular Compositions and Methods for Their Preparation Download PDFInfo
- Publication number
- US20100075295A1 US20100075295A1 US12/568,443 US56844309A US2010075295A1 US 20100075295 A1 US20100075295 A1 US 20100075295A1 US 56844309 A US56844309 A US 56844309A US 2010075295 A1 US2010075295 A1 US 2010075295A1
- Authority
- US
- United States
- Prior art keywords
- hepatocytes
- preparation
- viable
- cells
- hepatocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 95
- 238000000034 method Methods 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title abstract description 14
- 230000001413 cellular effect Effects 0.000 title 1
- 210000003494 hepatocyte Anatomy 0.000 claims abstract description 314
- 238000005138 cryopreservation Methods 0.000 claims abstract description 51
- 238000010257 thawing Methods 0.000 claims abstract description 16
- 241000282414 Homo sapiens Species 0.000 claims description 42
- 230000002503 metabolic effect Effects 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 19
- 239000002676 xenobiotic agent Substances 0.000 claims description 19
- 238000000338 in vitro Methods 0.000 claims description 18
- 108010071233 dextromethorphan O-demethylase Proteins 0.000 claims description 15
- 102000002237 Cytochrome P-450 CYP2A6 Human genes 0.000 claims description 14
- 108010000080 Cytochrome P-450 CYP2A6 Proteins 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 12
- TZCPWCWBUUWOBB-LQLPOJMZSA-N [(3s,7s,8s,9s,10r,13r,14s,17r)-7-hydroxy-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] octadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1[C@H](O)C=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 TZCPWCWBUUWOBB-LQLPOJMZSA-N 0.000 claims description 11
- 108010065311 tolbutamide 4-hydroxylase Proteins 0.000 claims description 11
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 claims description 10
- 238000005119 centrifugation Methods 0.000 claims description 9
- 230000036267 drug metabolism Effects 0.000 claims description 9
- 230000002034 xenobiotic effect Effects 0.000 claims description 8
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 229960003604 testosterone Drugs 0.000 claims description 6
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 claims description 6
- 241000283984 Rodentia Species 0.000 claims description 5
- TZFWDZFKRBELIQ-UHFFFAOYSA-N chlorzoxazone Chemical compound ClC1=CC=C2OC(O)=NC2=C1 TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960003633 chlorzoxazone Drugs 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 229960003893 phenacetin Drugs 0.000 claims description 5
- 230000031143 xenobiotic glucuronidation Effects 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000282465 Canis Species 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 4
- 241000282324 Felis Species 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008119 colloidal silica Substances 0.000 claims description 4
- 238000005194 fractionation Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 abstract description 102
- 230000035899 viability Effects 0.000 abstract description 33
- 238000012545 processing Methods 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 description 31
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 29
- 239000002609 medium Substances 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 23
- 238000003556 assay Methods 0.000 description 23
- 241000700159 Rattus Species 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000007710 freezing Methods 0.000 description 16
- 230000008014 freezing Effects 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 239000013256 coordination polymer Substances 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 238000003860 storage Methods 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 13
- 108010016702 7-Alkoxycoumarin O-Dealkylase Proteins 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 238000005805 hydroxylation reaction Methods 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 230000004060 metabolic process Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000009088 enzymatic function Effects 0.000 description 8
- 210000005229 liver cell Anatomy 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 6
- 239000002577 cryoprotective agent Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 5
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 5
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012595 freezing medium Substances 0.000 description 5
- 230000033444 hydroxylation Effects 0.000 description 5
- 238000011176 pooling Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 231100000041 toxicology testing Toxicity 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 239000012520 frozen sample Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 102000018832 Cytochromes Human genes 0.000 description 3
- 108010052832 Cytochromes Proteins 0.000 description 3
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 229960000956 coumarin Drugs 0.000 description 3
- 235000001671 coumarin Nutrition 0.000 description 3
- 230000000959 cryoprotective effect Effects 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 229960001985 dextromethorphan Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960000906 mephenytoin Drugs 0.000 description 3
- GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 3
- 210000004738 parenchymal cell Anatomy 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229960005371 tolbutamide Drugs 0.000 description 3
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 2
- LIFAQMGORKPVDH-UHFFFAOYSA-N 7-ethoxycoumarin Chemical compound C1=CC(=O)OC2=CC(OCC)=CC=C21 LIFAQMGORKPVDH-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960002135 sulfadimidine Drugs 0.000 description 2
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 230000022814 xenobiotic metabolic process Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WPHAFLPTWKYNHB-UHFFFAOYSA-N 3-hydroxychromen-2-one Chemical compound OC=1C(OC2=CC=CC=C2C1)=O.OC=1C(OC2=CC=CC=C2C1)=O WPHAFLPTWKYNHB-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 240000008100 Brassica rapa Species 0.000 description 1
- XQAGFWRYBIKNNS-UHFFFAOYSA-N C(C)OC1=CC=C2C=CC(OC2=C1)=O.C(C)OC=1C(OC2=CC=CC=C2C1)=O Chemical compound C(C)OC1=CC=C2C=CC(OC2=C1)=O.C(C)OC=1C(OC2=CC=CC=C2C1)=O XQAGFWRYBIKNNS-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000178041 Ceropegia media Species 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108010069156 Connexin 26 Proteins 0.000 description 1
- 102000055974 Connexin 26 Human genes 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102100037260 Gap junction beta-1 protein Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000884385 Homo sapiens Arylamine N-acetyltransferase 1 Proteins 0.000 description 1
- 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 description 1
- 101001034811 Homo sapiens Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 1
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 description 1
- 101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 description 1
- 101000631948 Homo sapiens Sodium-dependent proline transporter Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 108091006671 Ion Transporter Proteins 0.000 description 1
- 102000037862 Ion Transporter Human genes 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 108091006764 Organic cation transporters Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 101000927335 Pithecopus azureus Dermaseptin-H4 Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102100036916 Sodium-coupled neutral amino acid transporter 1 Human genes 0.000 description 1
- 102100033769 Sodium-coupled neutral amino acid transporter 3 Human genes 0.000 description 1
- 102100028114 Sodium-dependent proline transporter Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 101710148271 UDP-glucose:glycoprotein glucosyltransferase 1 Proteins 0.000 description 1
- 102100029151 UDP-glucuronosyltransferase 1A10 Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000019259 carbohydrate homeostasis Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 108010015416 connexin 32 Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006204 deethylation Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 230000031142 liver development Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LJOOSFYJELZGMR-UHFFFAOYSA-N umbelliferone sulfate Chemical compound C1=CC(=O)OC2=CC(OS(=O)(=O)O)=CC=C21 LJOOSFYJELZGMR-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
Definitions
- the present invention relates to novel cell (e.g., hepatocyte, etc.) compositions and methods for their preparation and use.
- the invention concerns methods of processing preparations of such cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability.
- the invention also concerns preparations of cells (e.g., hepatocytes) that have been repeatedly cryopreserved and thawed.
- Hepatocytes are parenchymal liver cells, and make up 60-80% of the cytoplasmic mass of the liver. Hepatocytes play a key role in the detoxification, modification and excretion of exogenous and endogenous substances (Ponsoda, X. et al. (2004) “ Drug Metabolism By Cultured Human Hepatocytes: How Far Are We From The In Vivo Reality ?” Altern. Lab Anim. 32(2):101-110).
- One of the detoxifying functions of hepatocytes is to modify ammonia to urea for excretion. They are also important in protein synthesis and storage, in the transformation of carbohydrates and in the synthesis of cholesterol, bile salts and phospholipids (Postic, C. et al.
- the hepatocyte is the only cell in the body that manufactures albumin, fibrinogen, and the prothrombin group of clotting factors. It is the main site for the synthesis of lipoproteins, ceruloplasmin, transferrin, and glycoproteins. Hepatocytes manufactures their own structural proteins and intracellular enzymes. Hepatocytes are also important depots for vitamin B12 and iron.
- hepatocytes In addition to their use in liver models, hepatocytes have the potential of being used to produce Bioartificial Livers (BALs) or in hepatocyte transplantation that can provide liver functions for individuals suffering from liver disease or liver failure.
- Bioartificial Livers (BALs) are described by Anand, A. C. (1996) “ Bioartificial Livers: The State Of The Art ,” Trop Gastroenterol. 17(4):197-198, 202-211; Gan. J. H. et al. (2005) “ Hybrid Artificial Liver Support System For Treatment Of Severe Liver Failure ,” World J. Gastroenterol. 11(6):890-894; Fukuda, J. et al.
- a cryoprotectant such as glycerol, DMSO, polyvinylpyrrolidone, or dextrin
- a cryoprotectant such as glycerol, DMSO, polyvinylpyrrolidone, or dextrin
- the art has developed various freezing procedures, all designed to minimize or prevent the occurrence of intracellular ice.
- the freezing rates typically vary from ⁇ 0.05° C./min to ⁇ 50° C./min (see, Lloyd, T. D. R. et al. (2003) Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking,” Cell and Tissue Culture Banking 4:3-15).
- cryopreservation has been found to cause a significant decrease in cellular viability (e.g., 25-35%) (Dou, M. et al. (1992) “ Thawed Human Hepatocytes In Primary Culture ,” Cryobiology 29:454-469; Alexandre, E. et al. (2002) “ Cryopreservation Of Adult Human Hepatocytes Obtained From Resected Liver Biopsies ,” Cryobiology 44:103-113).
- Coundouris, J. A. et al. (1993) reported viability of 67% after 24 hours, declining to 49% after 14 days (Coundouris, J.
- a second major problem affecting the use of both fresh and cryopreserved hepatocytes is the variation of liver enzyme expression that is observed in tissue from different donors (Li. A. P. et al. (1999) “ Present Status Of The Application Of Cryopreserved Hepatocytes In The Evaluation Of Xenobiotics: Consensus Of An International Expert Panel ,” Chem Biol Interact. 121(1):117-123; Li, A. P. et al. (1999) “ Cryopreserved Human Hepatocytes: Characterization Of Drug - Metabolizing Enzyme Activities And Applications In Higher Throughput Screening Assays For Hepatotoxicity, Metabolic Stability, And Drug - Drug Interaction Potential ,” Chem Biol Interact.
- the present invention permits the production and availability of hepatocyte preparations that may be repeatedly cryopreserved and thawed without unacceptable loss of viability.
- the invention thus permits multiple hepatocyte samples to be pooled to produce pooled hepatocyte preparations, especially pooled cryopreserved human hepatocyte preparations. Using such advance, pooled cryopreserved human hepatocytes are now commercially available from In Vitro Technologies (Baltimore, Md.).
- the present invention relates to novel cell (e.g., hepatocyte) compositions and methods for their preparation and use.
- the invention concerns methods of processing preparations of cells, especially hepatocytes, so as to permit their repeated cryopreservation and thawing while retaining substantial viability.
- the invention also concerns preparations of cells (e.g., hepatocytes) that have been repeatedly cryopreserved and thawed.
- the invention particularly concerns a multi-cryopreserved hepatocyte preparation comprising hepatocytes that have been frozen and thawed at least two times, wherein greater than 50% and more preferably 70% or more of the hepatocytes of the preparation are viable.
- the invention further concerns the embodiment of such a multi-cryopreserved hepatocyte preparation wherein the hepatocytes are selected from the group consisting of human hepatocytes, porcine hepatocytes, simian hepatocytes, canine hepatocytes, feline hepatocytes, bovine hepatocytes, equine hepatocytes, ovine hepatocytes and rodent hepatocytes.
- the invention further concerns the embodiment of such a multi-cryopreserved hepatocyte preparation wherein the preparation comprises a pooled preparation of hepatocytes of multiple sources, which may be of the same or different gender, race, or health state, or which provide the pooled preparation with a desired level of a metabolic activity (especially wherein the metabolic activity is selected from the group consisting of COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, PHEN and CZX).
- the invention further concerns a method of producing a desired preparation of multi-cryopreserved hepatocytes, the hepatocytes being capable of being frozen and thawed at least two times, and in which greater than 50% and more preferably 70% or more of the hepatocytes of the preparation are viable, the method comprising:
- the invention further concerns the embodiment of such a method in which the hepatocytes are selected from the group consisting of human hepatocytes, porcine hepatocytes, simian hepatocytes, canine hepatocytes, feline hepatocytes, bovine hepatocytes, equine hepatocytes, ovine hepatocytes and rodent hepatocytes.
- the invention further concerns the embodiment of such a method in which the preparation comprises a pooled preparation of hepatocytes of multiple sources, which may be of the same or different gender, race, or health state, or which provide the pooled preparation with a desired level of a metabolic activity (especially wherein the metabolic activity is selected from the group consisting of COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, PHEN and CZX).
- the invention also concerns a method of investigating in vitro drug metabolism comprising incubating hepatocytes of a multi-cryopreserved hepatocyte preparation in the presence of a xenobiotic, and determining the metabolic fate of the xenobiotic, or the effect of the xenobiotic on the hepatocytes or on an enzyme or metabolic activity thereof wherein the hepatocytes have been frozen and thawed at least two times, and wherein greater than 50% and more preferably 70% or more of the hepatocytes of the preparation are viable.
- the present invention relates to novel cell compositions and methods for their preparation and use.
- the invention concerns methods of processing preparations of cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability.
- the methods of the present invention are generally applicable to a wide variety of cell types, including hepatocytes, kidney cells, spleen cells, thymus cells, bone marrow cells, stem cells, muscle cells (including cardiac muscle cells), endocrine cells (including pancreatic cells, adrenal cells, thyroid cells, etc.) epidermal cells, endodermal cells, etc.
- the methods of the present invention are illustrated below with respect to a preferred cell type: hepatocytes.
- the invention also concerns preparations of cells, e.g., hepatocytes, that have been repeatedly cryopreserved and thawed to obtain a high viability preparation useful for a variety of experimental, diagnostic and therapeutic purposes.
- the present invention extends the ability of hepatocytes to be cryopreserved and thawed for later use, so as to permit hepatocyte preparations to be repeatedly cryopreserved and thawed without an unacceptable loss of viability.
- the term “cell preparation” denotes a liquid or frozen composition of cells from one or more sources (e.g., “hepatocyte preparation”, denotes a composition of liver cells from one or more sources).
- the sources may be primary cells that have been dissociated from or isolated from tissue as by resection, biopsy, or from donor organs, or they may be secondary, immortalized or transformed cell cultures.
- the cells may be derived from any mammalian source, including human, porcine, simian, canine, feline, bovine, equine, ovine or rodent sources. The use of human, porcine or rodent (especially rat) cells is preferred.
- greater than 50% and more preferably 70% or more of the hepatocytes of such preparations will be viable.
- multi-cryopreserved cell preparation denotes a cell preparation that has been frozen and then thawed at least two times (e.g., a “multi-cryopreserved hepatocyte preparation” denotes a hepatocyte preparation that has been frozen and then thawed at least two times). Such preparations may have been frozen and thawed three, four, five, or more times.
- the term “pooled preparation” denotes a cell (e.g., hepatocyte) preparation in which the cells (e.g., hepatocytes) are derived from two, three, four, five, or more different sources, such as different donors, biopsies, tissue resections from different tissue samples or different tissue sources, or different primary, secondary, immortalized or transformed cell (e.g., hepatocyte) cultures.
- the cells e.g., hepatocytes
- different sources such as different donors, biopsies, tissue resections from different tissue samples or different tissue sources, or different primary, secondary, immortalized or transformed cell (e.g., hepatocyte) cultures.
- the cells of such pooled preparations may be randomly selected cell, or may have been selected to provide the pooled preparation with a desired level of one or more metabolic activities (such as for example, a preparation of hepatocytes having a desired level of COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, PHEN and/or CZX activity), or a desired cell characteristic (such as, for example, a preparation of hepatocytes derived from sources of the same gender, age, race (e.g., Caucasian, etc.), or health state (e.g., hepatocytes of hepatitis virus-infected liver, hepatocytes of HIV-1 infected liver, hepatocytes of healthy liver, hepatocytes of cigarette smokers, hepatocytes of individuals suffering from cirrhosis of the liver, or from other diseases or conditions).
- a pooled preparation could be randomly selected cell, or may have been selected to provide the pooled preparation with
- the practice of the invention comprises some or all of the following steps: the isolation of hepatocytes, a first cryopreservation of the isolated primary hepatocytes to obtain a first cryopreserved hepatocyte preparation, the thawing of the first cryopreserved hepatocyte preparation to obtain viable hepatocytes, and the reformulation of the thawed viable hepatocytes to permit their further storage and use through repeated cryopreservation and thawing to obtain viable hepatocytes.
- any of a wide variety of methods may be employed or adapted to permit the isolation of the primary hepatocytes used in the present invention.
- suitable techniques for the isolation of hepatocytes are outlined in Morsiani et al, (1995) “ Automated Liver Cell Processing Facilitates Large Scale Isolation And Purification Of Porcine Hepatocytes,” ASAIO Journal 41:155-161 and in Seglen, P. O. (1976) “ Preparation Of Isolated Rat Liver Cells,” Meth. Cell Biol. 13:29-83).
- Specific reference is made to the two-step collagenase digestion procedure described in Li, A. P. et al. (1992) “ Isolation And Culturing Of Hepatocytes From Human Liver,” J. Tissue Cult. Meth. 14:139-146.
- the hepatocytes may be cultured in any suitable hepatocyte culture medium.
- any suitable hepatocyte culture medium By way of illustration and not limitation mention may be made of the following culture media Chee's Essential Media (Hamilton, G. A. et al. (2001) “ Effects Of Medium Composition On The Morphology And Function Of Rat Hepatocytes Cultured As Spheroids And Monolayers ,” In Vitro Cell Dev Biol Anim. 37(10):656-667; Zurlo, J. et al. (1996) “ Characterization Of A Primary Hepatocyte Culture System For Toxicological Studies ,” In Vitro Cell Dev Biol Anim. 32(4):211-220; Arterburn, L. M. et al.
- hepatocytes are cryopreserved in a medium containing approximately 10% DMSO and approximately 90% fetal bovine serum (Loretz, L. J. et al. (1989) “ Optimization Of Cryopreservation Procedures For Rat And Human Hepatocytes,” Xenobiotics 19:489-498; Ruegg, C. E. et al. (1997) “ Cytochrome - P 450 Induction and Conjugated Metabolism In Primary Human Hepatocytes After Cryopreservation ,” In Vitro Toxicol. 10:217-222).
- the viability of the isolated hepatocytes may be determined using any of a variety or methods. Preferable, such viability will be determined using the Trypan blue exclusion method (see, e.g., Berry, M. N. et al. (1992) “ Techniques For Pharmacological And Toxicological Studies With Isolated Hepatocyte Suspensions ,” Life Sci. 51(1):I-16). Thus the phrases “viable hepatocytes” or “percent viability”, as used herein, refers to hepatocyte viability as assessed using the method of Trypan Blue exclusion.
- the hepatocytes of the present invention are preferably cryopreserved using liquid nitrogen, and most preferably within 36 hours of their isolation. Considerations for the cryopreservation of human hepatocytes are discussed in Lloyd, T. D. R. et al. (2003) Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking,” Cell and Tissue Culture Banking 4:3-15. Suitable procedures for the cryopreservation of hepatocytes may also be found in the following documents: Adams, R. M. et al. (1995) “ Effective Cryopreservation And Long - Term Storage Of Primary Human Hepatocytes With Recovery Of Viability, Differentiation, And Replicative Potential ,” Cell Transplant.
- isolated hepatocytes are suspended in a cryoprotective medium, and the suspended cells are dispensed into freezer-safe containers.
- a cryoprotective medium typically comprises a hepatocyte culture medium that contains at least one cryoprotectant that minimizes the deleterious effects of cryopreservation such as the formation of intracellular ice during freezing.
- cryoprotectants dimethylsulfoxide (DMSD), polyethylene glycol, amino acids, propanediol, and glycerol.
- DMSD dimethylsulfoxide
- a preferred cryoprotectant of the present invention is DMSD.
- DMSD dimethylsulfoxide
- Suitable cryoprotectants and methods for their use in hepatocyte cryopreservation can be found, for example, in: Lore, L. J.
- the isolated hepatocytes are preferably suspended in a cryoprotective medium in preparation for freezing.
- the suspended cells are preferably dispensed into freezer resistant containers at a cell density of from about 105 cells/ml to about 4 ⁇ 10′ cells/ml.
- Preferred freezing volumes range from 0.1-10.0 ml.
- the preferred freezing volume is 1.0 ml.
- the dispensed hepatocytes are then preferably cryopreserved using a controlled rate freezing process, most preferably at a freezing rate of between about ⁇ 1° C./min to about ⁇ 25° C./min until a final temperature of about ⁇ 90° C. is reached.
- seeding may be employed to induce controlled crystallization or ice formation in cell suspensions that have already been cooled to below the freezing point of the culture medium. Such seeding serves to minimize ice formation-related damage and therefore may be beneficial to cell viability.
- Suitable seeding methods include inserting a cold metal rod into the freezing containers, and introducing a blast of liquid nitrogen into the freezing containers.
- the frozen cell samples may be transferred to liquid nitrogen freezers for prolonged storage.
- the frozen samples may be stored in either the liquid nitrogen phase or the gas phase of liquid nitrogen. Preferably storage is accomplished in the gas phase of liquid nitrogen.
- the frozen samples may be stored in this manner for days, months, or years, with the length of storage in the gas phase of liquid nitrogen having little effect on the post-thaw viability and function.
- Frozen samples may be thawed for further processing by removing them from the presence of liquid nitrogen or liquid nitrogen vapor.
- Frozen samples are preferably thawed by placing the samples immediately into a prewarmed water bath having a temperature of between about 37° C. to about 42° C.
- cells are thawed to at least the stage in which ice chunks can be dislodged when the sample container is inverted.
- the thawed cells are then preferably rapidly processed to remove the cells from contact with DMSO, for example by PERCOLL® (colloidal silica particles of 15-30 nm diameter (23% w/w in water) which have been coated with polyvinylpyrrolidone (PVP)) gradient centrifugation (as described below) or by sequential washings.
- PERCOLL® colloidal silica particles of 15-30 nm diameter (23% w/w in water) which have been coated with polyvinylpyrrolidone (PVP)) gradient centrifugation (as described below) or by sequential washings.
- PVP polyvinylpyrrolidone
- the cells are thawed into Complete INVITROGROTM CP medium (In Vitro Technologies, Baltimore, Md.; Roymans. U. et al. (2004) “ Determination Of Cytochrome P 450 IA 2 And Cytochrome P 4503 a 4 Induction In Cryopreserved Human Hepatocytes ,” Biochem. Pharmacol. 67(3):427-437) (hepatocyte plating medium, which contains water, Dulbecco's Modified Eagle Medium, sodium bicarbonate, HEPES, fructose, bovine serum albumin, sodium hydroxide, MEM non-essential amino acids, insulin, hydrocortisone, and newborn calf serum).
- Complete INVITROGROTM CP medium In Vitro Technologies, Baltimore, Md.; Roymans. U. et al. (2004) “ Determination Of Cytochrome P 450 IA 2 And Cytochrome P 4503 a 4 Induction In Cryopreserved Human Hepatocytes ,”
- the medium is prepared by thawing TORPEDOTM Antibiotic Mix (In Vitro Technologies, Baltimore, Md.) (a mixture of antibiotics selected to inhibit bacterial growth in hepatocyte cell cultures that contains penicillin, streptomycin, gentamicin, amikacin and fungizone) to 37° C. in a water bath until thawed, and then removed from the water bath.
- TORPEDOTM Antibiotic Mix a mixture of antibiotics selected to inhibit bacterial growth in hepatocyte cell cultures that contains penicillin, streptomycin, gentamicin, amikacin and fungizone
- the thawed contents are then emptied into the pre-warmed INVITROGROTM CP medium.
- 1.0 ml of pre-warmed INVITROGROTM CP medium then is added to each vial to resuspend any remaining cells.
- the contents of the vial are then decanted or pipetted into the hepatocyte suspension.
- the hepatocytes are preferably resuspended by gently inverting the receiving container (e.g., vial, test rube, etc.) several (e.g., three) times.
- the medium preferably, INVITROGROTM CP medium
- the medium should be warmed to 37° C. It is desirable to ensure that there is enough medium to permit 5 ml of pre-warmed INVITROGROTM CP medium to he used for each vial of cryopreserved hepatocytes.
- their caps should be quickly removed and their contents poured into a sterile tube or beaker that contains at least 5 ml of pre-warmed INVITROGROTM CP medium per vial thawed.
- 25 ml of media is preferably employed for 5 vials in a container that can hold a volume of 50 ml.
- the total cell count and the number of viable cells may be determined using the Trypan Blue exclusion method. Cells may he diluted to 0.70 ⁇ 10 6 viable cells/ml with INVITROGROTM CP medium.
- One aspect of the present invention concerns the ability to reformulate the thawed cells so that they may be refrozen and rethawed on one or more subsequent occasions.
- Such multi-cryopreserved hepatocyte preparations have multiple uses. They may be used in bioartificial livers, liver cell transplants, liver assist devices, hepatocyte transplantations, and in vitro applications.
- multi-cryopreserved hepatocyte preparations may be used in in vitro drug metabolism studies (for example, in identifying hepatocytes with unique characteristics (e.g., metabolic polymorphisms, genetic polymorphisms, etc.), in studies on the metabolic fate of the xenobiotic and studies on the affect of the xenobiotic in altering the drug-metabolizing enzyme profile of the hepatocytes, in inhibition studies to determine the IC50 of xenobiotics on liver enzymes and functions (e.g.
- Multi-cryopreserved hepatocyte preparations may also be used to study or propagate hepatitis viruses and other infectious viruses and agents.
- Recovered cells may be reformulated for use in DNA, mRNA or proteomic studies or in studies of metabolic polymorphisms. Multi-cryopreserved hepatocyte preparations may also be used in metabolic clearance studies and efficacy assays (e.g., lipoprotein processing, gluconeogenesis, protein secretion, etc.). Cells may be reformulated for use in seeding bioreactors for large scale incubations or as models for gene regulation via micro RNA, or for use in combination systems with other cell types (e.g. non-parenchymal cells from liver or cells from other sources, e.g. Caco-2 cells).
- multi-cryopreserved hepatocyte preparations may also be used in metabolic clearance studies and efficacy assays (e.g., lipoprotein processing, gluconeogenesis, protein secretion, etc.).
- Cells may be reformulated for use in seeding bioreactors for large scale incubations or as models for gene regulation via micro RNA,
- such reformulation comprises separating viable and non-viable cells prior to a subsequent refreezing.
- Density gradient centrifugation is preferably employed for this purpose.
- a 30% PERCOLL® gradient centrifugation procedure may be employed (Madan. A. et al. (1999) “Effect of Cryopreservation on Cytochrome P-450 Enzyme Induction in Cultured Rat Hepatocytes, Drug Metab. Dispos. 27(3):327-335; Sun, E. L. et al.
- the thawed cells may be resuspended in a prewarmed (approximately 37° C.) 30% PERCOLL® isotonic fractionation buffer and then centrifuged at 100 ⁇ g at room temperature for twenty minutes to pellet viable cells. The supernatant is discarded and the cells are resuspended in media for a subsequent cryopreservation step directly or for further processing prior to cryopreservation.
- Cryopreserved preparations that result from the freezing of a previously frozen-thawed preparation will preferably have a post-thaw cell viability of greater than 50% and more preferably 70% or more.
- Such high viabilities enable the present invention to accomplish the repeated freezing and thawing of hepatocytes without unacceptable losses of cells or the need for ever greater samples sources.
- the capacity of the present invention to enable the repeated freezing and thawing of hepatocytes additionally facilitates the production of pooled hepatocyte preparations, especially pooled human hepatocyte preparations.
- individual liver samples yield hepatocytes having differing metabolic capabilities.
- Such composite hepatocyte preparations may thus be formulated so as to provide a preparation having the metabolic activities of an “average” hepatocyte sample or a preparation whose hepatocyte enzyme functions approximate the hepatocyte enzyme functions of freshly isolated hepatocytes.
- Such metabolic activities may include, for example, some or all of the following enzymatic activities: coumarin 7-hydroxylase (COUM), dextromethorphan O-demethylase (DEX), 7-ethoxycoumarin O-deethylase (ECOD), activities responsible for the phase II metabolism of 7-hydroxycoumarin (7-HCG and 7-HCS), mephenyloin 4-hydroxylase (MEPH), testosterone 6(B)-hydroxylase (TEST), tolbutamide 4-hydroxylase (TOLB), phenacetin O-deethylase (PHEN), or chlorzoxazone 6-hydroxylase (CZX).
- COUM coumarin 7-hydroxylase
- DEX dextromethorphan O-demethylase
- COD 7-ethoxycoumarin O-deethylase
- activities responsible for the phase II metabolism of 7-hydroxycoumarin (7-HCG and 7-HCS mephenyloin 4-hydroxylase (MEPH), testosterone 6(B)-hydroxylase (TEST),
- preferred preparations of pooled hepatocytes will yield assay values within the ranges identified in Table II.
- the hepatocytes samples used to form the pooled preparation may be selected so as to maximize, minimize, or emphasize certain hepatocyte functions over other functions so as to yield a pooled preparation that exhibits a user desired profile of liver cell function(s).
- the pooled hepatocyte preparations of the present invention may comprise hepatocytes obtained from the same source at differing times, or from two or more different sources.
- pooled hepatocyte preparations will result from the pooling of hepatocytes obtained from three, four, five, six or more different sources.
- the pooled hepatocyte preparations of the invention will comprise at least one population of hepatocytes that were cryopreserved prior to pooling.
- a pooled hepatocyte preparation may comprise one or more hepatocyte specimens that were cryopreserved prior to pooling with one or more freshly isolated hepatocyte specimens.
- a pooled hepatocyte preparation may comprise only hepatocyte specimens that were previously cryopreserved.
- Table II provides the normal range (i.e., the range between Assay Minimum and Assay Maximum for each Assay). Table II values are derived data of the last 150+ lots of human cryopreserved hepatocytes.
- hepatocyte preparations will have assay values in the above stated ranges for at least three of, and preferably for at least four of, still more preferably for at least six of, and most preferably for at least eight of the following assays: the COUM assay; the DEX assay; the ECOD assay; the 7-HCG assay; the 7-HCS assay; the MEPH assay; the TEST assay; the TOLB assay; the PHEN assay; the CZX assay.
- cryopreserved hepatocytes may be plated on to collagen-coated tissue culture plates, or tissue culture plates coated with other extracellular matrix proteins including but not limited to laminin, fibronectin, entactin, poly-L-lysine, gelatin, or any combination thereof.
- this is accomplished by diluting an appropriate volume (e.g., 0.2 ml to 2.5 ml) of diluted cells (e.g., cells having a concentration of approximately 0.7 ⁇ 106 cells/ml) onto the plates.
- the cell suspension For plating on a 96-well microliter plate, it is desirable to further dilute the cell suspension to a concentration of 0.35 ⁇ 106 cells/ml with INVITROGROTM Medium, and to add 100 ⁇ l of the cell suspension to each well. It is preferred to even distribute the cells in the wells. This can be accomplished by gently shaking the plates in a back-and-forth and side-to-side manner; the use of a circular motion will cause the cells to evenly pool in the center of the wells. Human hepatocytes handled in this manner will attach to the plates in 2-4 hours, however, if minimal handling is desired, the cells can be allowed to attach overnight.
- Cryopreserved hepatocytes are thawed and refrozen as indicated below.
- PERCOLL®/REDIGRADTM (Amersham Biosciences) is employed for the PERCOLL® density centrifugation.
- PERCOLL® is composed of colloidal silica coated with polyvinylpyrrolidone (PVP).
- PVP polyvinylpyrrolidone
- REDIGRADTM formulation is also composed of colloidal silica but is covalently coated with silane. These coatings are thought to render the material non-toxic and ideal for use with biological materials. Both particles have a density of 1.13 g/ml. Centrifugation of samples in the presence of PERCOLL®/REDIGRADTM results in the spontaneous formation of a density gradient due to the heterogeneity of particle sizes in the medium.
- PERCOLL®/REDIGRADTM is best used in balanced salt solutions, such as physiological saline (0.15M NaCl), although 0.25 M sucrose may be employed.
- the addition of 9 parts (v/v) of PERCOLL®/REDIGRADTM to 1 part (v/v) of either 1.5 M NaCl, 10 ⁇ concentrated cell culture medium, or 2.5 M sucrose will result in a solution adjusted to about 340 mOs/kg H 2 O, Solutions of different osmotic pressure can be produced by adjusting the relative volumes of PERCOLL®/REDIGRADTM and salt or sucrose solution.
- PERCOLL®/REDIGRADTM will form self-generated gradients by centrifugation in fixed-angle rotor heads after 15 minutes. Hepatocytes can be separated by centrifugation at 50-100 g av in fixed-angle or swinging bucket rotor heads after 10-30 minutes.
- hepatocytes are isolated from 82 different donors and analyzed for cell viability and enzyme function. The following metabolic activities are evaluated: COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, TOLB, PHEN, and CZX. The results are shown in Table III.
- Cryopreserved pooled lots of hepatocytes are prepared and analyzed for post-thaw viability and enzyme function. The following metabolic activities are evaluated: COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, TOLB, PHEN, and CZX.
- hepatocytes Six lots of pooled hepatocytes, comprising either five-donor pools or ten-donor pools, are prepared as described above. Hepatocytes are harvested from individual donors and then cryopreserved as individual lots using liquid nitrogen as freezing agent. Cryopreservation is accomplished by suspending the hepatocytes into freezer-safe vials containing a medium having approximately 10% DMSD and approximately 90% Cryopreservation Medium. The dispensed hepatocytes are then frozen in a controlled rate freezer until a final temperature of approximately ⁇ 80° C. is reached.
- hepatocyte preparations To form the pooled hepatocyte preparations, individual lots are thawed, and the viable cells are isolated by PERCOLL® gradient centrifugation. Vials of individual donor cryopreserved hepatocytes were thawed in a 37° C. waterbath (perhaps it would be better to give a range such as 30-40° C. waterbath?) for 60-90 seconds. The thawed cells are decanted into 37° C. media containing 30% Isotonic PERCOLL® and 70% CP-2 media. The cell suspension is centrifuged at 100 g for 20 minutes. The viable cells are recovered in cryopreservation media and counted. The viable cells are diluted to 20 million cells per mL.
- a second solution containing 20% DMS4 and 80% cryopreservation media (equal volume to the cell suspension listed above) is prepared.
- the 20% DMSO and 80% cryopreservation media is slowly added to the cells suspension mixture. The addition takes 5-10 minutes.
- the resulting mixture is 10% DMSO, 90% cryopreservation media with cells at 10 million cells per mL. This solution is aliquoted into cryovials at 1.0 mL per vial. The cells are then cryopreserved. Viable cells from individual lots are then pooled to form pooled hepatocyte preparations whose cells have functional assay values within desired ranges.
- Table IV shows the results of the post-thaw viability (“% V”) and enzyme function analysis of the pooled lots. As indicated in Table III, pools had an average viability of 79% (S.D. ⁇ 6%).
- Table V shows summary data for a post-thaw viability and enzyme function analysis of eighty-one individual lots that are cryopreserved (i.e., subjected to one cycle of cryopreservation). This data confirms that the lot-to-lot variability of enzyme function found in individual hepatocyte sources is very high. The data confirms the desirability of employing pooled hepatocyte preparations for providing cryopreserved cells that approximate the enzyme function of “average” hepatocytes for a wide variety of enzymes.
- cryopreserved hepatocytes A common use of for cryopreserved hepatocytes is to thaw the hepatocytes and then incubate them with various xenobiotics. For this purpose, it is preferred that the hepatocytes maintain their viability for at least several hours. To examine the post-thaw viability over time for one lot of pooled cryopreserved hepatocytes, the cells were thawed, aliquoted into the wells of a 12-well plate, and incubated at 37° C. with 5% CO 2 . The viability of the hepatocytes is then measured at time-points for up to six hours. Table VI shows the results of this analysis, wherein, at six hours, 39% of the hepatocytes remained viable
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 11/110,879, filed Apr. 21, 2005, which application is herein incorporated by reference in its entirety.
- The present invention relates to novel cell (e.g., hepatocyte, etc.) compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of such cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The invention also concerns preparations of cells (e.g., hepatocytes) that have been repeatedly cryopreserved and thawed.
- Hepatocytes are parenchymal liver cells, and make up 60-80% of the cytoplasmic mass of the liver. Hepatocytes play a key role in the detoxification, modification and excretion of exogenous and endogenous substances (Ponsoda, X. et al. (2004) “Drug Metabolism By Cultured Human Hepatocytes: How Far Are We From The In Vivo Reality?” Altern. Lab Anim. 32(2):101-110). One of the detoxifying functions of hepatocytes is to modify ammonia to urea for excretion. They are also important in protein synthesis and storage, in the transformation of carbohydrates and in the synthesis of cholesterol, bile salts and phospholipids (Postic, C. et al. (2004) “Role Of The Liver In The Control Of Carbohydrate And Lipid Homeostasis,” Diabetes Metab. 30(5):398-408). The hepatocyte is the only cell in the body that manufactures albumin, fibrinogen, and the prothrombin group of clotting factors. It is the main site for the synthesis of lipoproteins, ceruloplasmin, transferrin, and glycoproteins. Hepatocytes manufactures their own structural proteins and intracellular enzymes. Hepatocytes are also important depots for vitamin B12 and iron.
- Due to these attributes, isolated and cultured hepatocytes have become very attractive as models systems for the study of liver functions (Chesne, C. et al. (1993) “Viability And Function In Primary Culture Of Adult Hepatocytes From Various Animal Species And Human Beings After Cryopreservation,” Hepatology 18(2):406-414; Guillouzo, A. et al. (1986) “Isolated and Cultured Hepatocytes,” Paris: les Editions INSERM and London: John Libbey Eurotext); Ponsoda. X. et al. (2004) “Drug Metabolism By Cultured Human Hepatocytes: How Far Are We From The In Vivo Reality?” Altern. Lab Anim. 32(2):101-110; Gomez-Lechon, M. J. et al. (2004) “Human Hepatocytes In Primary Culture: The Choice To Investigate Drug Metabolism In Man,” Curr. Drug Metab. 5(5):443-462; Lemaigre, F. et al. (2004) “Liver Development Update: New Embryo Models, Cell Lineage Control, And Morphogenesis,” Curr Opin Genet Dev. 14(5):582-590; Nanji, A. A. (2004) “Animal Models Of Nonalcoholic Fatty Liver Disease And Steatohepatitis,” Clin Liver Dis. 8(3):559-574; Hewitt, N. J. et al. (2004) Cryopreserved Rat, Dog And Monkey Hepatocytes: Measurement Of Drug Metabolizing Enzymes In Suspensions And Cultures.” Hum Exp Toxicol. 23(6):307-316).
- In addition to their use in liver models, hepatocytes have the potential of being used to produce Bioartificial Livers (BALs) or in hepatocyte transplantation that can provide liver functions for individuals suffering from liver disease or liver failure. Bioartificial Livers (BALs) are described by Anand, A. C. (1996) “Bioartificial Livers: The State Of The Art,” Trop Gastroenterol. 17(4):197-198, 202-211; Gan. J. H. et al. (2005) “Hybrid Artificial Liver Support System For Treatment Of Severe Liver Failure,” World J. Gastroenterol. 11(6):890-894; Fukuda, J. et al. (2004) “Hepatocyte Organoid Culture In Elliptic Hollow Fibers To Develop A Hybrid Artificial Liver,” hit J Artif Organs. 27(12):1091-1099; Meng, Q. et al. (2004) “Hepatocyte Culture In Bioartificial Livers With Different Membrane Characteristics,” Biotechnol Lett. 26(18):1407-1412; Sekido, H. et al. (2004) “Usefulness Of Artificial Liver Support For Pretransplant Patients With Fulminant Hepatic Failure,” Transplant Proc. 36(8):2355-2356; WO 03/105663A2, WO05/000376A2, and U.S. Pat. No. 6,759,245. Hepatocyte transplantation is described by Chan, C. et al. (2004) “Hepatic Tissue Engineering For Adjunct And Temporary Liver Support: Critical Technologies,” Liver Transpl. 10(11):1331-1342; Lee, S. W. et al. (2004) “Hepatocyte Transplantation: State Of The Art And Strategies For Overcoming Existing Hurdles,” Ann. Hepatol. 3(2):48-53; Horslen, S. P. (2004) “Hepatocyte Transplantation,” Transplantation 77(10): 1481-1486; Burlina, A. B. (2004) “Hepatocyte Transplantation For Inborn Errors Of Metabolism,” J. Inherit. Metab. Dis. 27(3):373-83; and Fox, I. J. et al. (2004) “Hepatocyte Transplantation,” Am. J. Transplant. 4 Suppl. 6:7-13.
- A limiting factor in the development of such model systems and to the development of Bioartificial Livers (BALs) has been the erratic source and limited availability of hepatocytes, especially human hepatocytes. Fresh hepatocytes are obtainable only from liver resections or non-transplantable livers of multi-organ donors (Lloyd, T. D. R. et al. (2003) Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking,” Cell and Tissue Culture Banking 4:3-15). The supply of such tissue is inconsistent and often geographically inconvenient in light of the limited functional lifespan of liver tissue (Smrzova, J. et al. (2001) “Optimization Of Porcine Hepatocytes Cryopreservation By Comparison Of Viability And Enzymatic Activity Of Fresh And Cryopreserved Cells,” Acta Veterinaria Brunensis 70:141-147).
- One approach to addressing this problem has involved the development of hepatocyte storage conditions that allow hepatocytes to be maintained over time with their cellular functions preserved. Cryopreservation methods for the storage of hepatocytes have been developed to address this need (see, Lloyd, T. D. R. et al. (2003) Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking,” Cell and Tissue Culture Banking 4:3-15; Loretz, L. J. et al. (1989) “Optimization Of Cryopreservation Procedures For Rat And Human Hepatocytes,” Xenobiotica. 19(5):489-498; Shaddock, J. G. et al. (1993) “Cryopreservation And Long-Term Storage Of Primary Rat Hepatocytes: Effects On Substrate-Specific Cytochrome P450-Dependent Activities And Unscheduled DNA Synthesis,” Cell Biol Toxicol. 9(4):345-357; Novicki, D. L. et al. (1982) “Cryopreservation Of structural proteins and intracellular enzymes. Hepatocytes are also important depots for vitamin B12 and iron. Isolated Rat Hepatocytes,” In Vitro. 18(4):393-399; Zaleski, J. et al. (1993) “Preservation Of The Rate And Profile Of Xenobiotic Metabolism In Rat Hepatocytes Stored In Liquid Nitrogen,” Biochem Pharmacol. 46(1):111-116). Typically, such measures comprise storage in liquid nitrogen (−196° C.) or in frozen nitrogen gas (−150° C.). The ability to recover viable thawed cells has been found to depend on multiple factors such as the rate of freezing, the concentration of hepatocytes, the type of cryoprotectant employed, and the final cooling temperature. Cell concentrations of 106-107 cells/ml have been typically employed. The isolated hepatocytes are typically incubated in suspension for a period (e.g., 4-48 hours) to allow them to recover from the isolation process. Thereafter, a cryoprotectant (such as glycerol, DMSO, polyvinylpyrrolidone, or dextrin) is added, and the hepatocytes are frozen. The art has developed various freezing procedures, all designed to minimize or prevent the occurrence of intracellular ice. The freezing rates typically vary from −0.05° C./min to −50° C./min (see, Lloyd, T. D. R. et al. (2003) Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking,” Cell and Tissue Culture Banking 4:3-15).
- While the development of cryopreservation methods for the storage of hepatocytes has significantly facilitated the availability of human hepatocytes, cryopreservation has been found to cause a significant decrease in cellular viability (e.g., 25-35%) (Dou, M. et al. (1992) “Thawed Human Hepatocytes In Primary Culture,” Cryobiology 29:454-469; Alexandre, E. et al. (2002) “Cryopreservation Of Adult Human Hepatocytes Obtained From Resected Liver Biopsies,” Cryobiology 44:103-113). Coundouris, J. A. et al. (1993) reported viability of 67% after 24 hours, declining to 49% after 14 days (Coundouris, J. A. et al. (1993) “Cryopreservation Of Human Adult Hepatocytes For Use In Drug Metabolism And Toxicity Studies.” Xenobiotica. 23(12):1399-1409). Adams, R. M. et al. have reported that the viability of hepatocytes may be enhanced to greater than 90% using specialized cyropreservation fluids, however, only 16% of cells were found to be capable of replication (Adams, R. M. et al. (1995) “Effective — Cryopreservation And Long-Terms Storage Of Primary Human Hepatocytes With Recovery Of Viability, Differentiation, And Replicative Potential,” Cell Transplant. 4(6):579-586). Methods of cryopreservation are disclosed in U.S. Pat. Nos. 5,795,711, 6,136,525, 5,895,745; International Patent Publications WO04/009766, WO92/12722, WO/0153462, European Patent No. EP0834252B, and United States Patent Applications Publication Nos. US20020039786A1, US20030134418A1. The poor recovery of cells when cryopreserved continues to limit the use of hepatocytes in in vitro liver models.
- A second major problem affecting the use of both fresh and cryopreserved hepatocytes is the variation of liver enzyme expression that is observed in tissue from different donors (Li. A. P. et al. (1999) “Present Status Of The Application Of Cryopreserved Hepatocytes In The Evaluation Of Xenobiotics: Consensus Of An International Expert Panel,” Chem Biol Interact. 121(1):117-123; Li, A. P. et al. (1999) “Cryopreserved Human Hepatocytes: Characterization Of Drug-Metabolizing Enzyme Activities And Applications In Higher Throughput Screening Assays For Hepatotoxicity, Metabolic Stability, And Drug-Drug Interaction Potential,” Chem Biol Interact. 121(1):17-35; O'Brien, Z. Z. et al. (undated) “The Construction Of A Representative Human Cryopreserved Hepatocyte Pool For Metabolism Study.” One solution to this sample variation involves pooling samples from different sources to produce a “composite” hepatocyte preparation having the characteristics of “average” liver cells. However, the frequency of receipt of fresh tissue and the need to cryopreserve hepatocytes immediately after isolation has been cited as preventing the preparation of hepatocyte pools. Thus, multiple companies (e.g., Xenotech, LLC; BD Biosciences) refrain from selling pooled hepatocytes thus forcing the end user to thaw and pool hepatocytes from several different donors. This difficulty remains even though pooled cryopreserved human hepatocytes are a valid model for metabolic studies (Zhang, J. G. et al. (undated) “Validation Of Pooled Cryopreserved Human Hepatocytes As A Model for Metabolic Studies.”
- Thus, despite all prior advances, a need remains for processes that would enable the availability of hepatocytes for medical research and other purposes. A need further exists for a stable and reproducible source of human hepatocytes. The present invention permits the production and availability of hepatocyte preparations that may be repeatedly cryopreserved and thawed without unacceptable loss of viability. The invention thus permits multiple hepatocyte samples to be pooled to produce pooled hepatocyte preparations, especially pooled cryopreserved human hepatocyte preparations. Using such advance, pooled cryopreserved human hepatocytes are now commercially available from In Vitro Technologies (Baltimore, Md.).
- The present invention relates to novel cell (e.g., hepatocyte) compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of cells, especially hepatocytes, so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The invention also concerns preparations of cells (e.g., hepatocytes) that have been repeatedly cryopreserved and thawed.
- In detail, the invention particularly concerns a multi-cryopreserved hepatocyte preparation comprising hepatocytes that have been frozen and thawed at least two times, wherein greater than 50% and more preferably 70% or more of the hepatocytes of the preparation are viable.
- The invention further concerns the embodiment of such a multi-cryopreserved hepatocyte preparation wherein the hepatocytes are selected from the group consisting of human hepatocytes, porcine hepatocytes, simian hepatocytes, canine hepatocytes, feline hepatocytes, bovine hepatocytes, equine hepatocytes, ovine hepatocytes and rodent hepatocytes.
- The invention further concerns the embodiment of such a multi-cryopreserved hepatocyte preparation wherein the preparation comprises a pooled preparation of hepatocytes of multiple sources, which may be of the same or different gender, race, or health state, or which provide the pooled preparation with a desired level of a metabolic activity (especially wherein the metabolic activity is selected from the group consisting of COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, PHEN and CZX).
- The invention further concerns a method of producing a desired preparation of multi-cryopreserved hepatocytes, the hepatocytes being capable of being frozen and thawed at least two times, and in which greater than 50% and more preferably 70% or more of the hepatocytes of the preparation are viable, the method comprising:
- (A) subjecting hepatocytes that have been frozen and thawed to density gradient fractionation (especially PERCOLL® density centrifugation) to separate viable hepatocytes from non-viable hepatocytes,
- (B) recovering the separated viable hepatocytes, and
- (C) cryopreserving the recovered viable hepatocytes to thereby form the desired preparation of hepatocytes.
- The invention further concerns the embodiment of such a method in which the hepatocytes are selected from the group consisting of human hepatocytes, porcine hepatocytes, simian hepatocytes, canine hepatocytes, feline hepatocytes, bovine hepatocytes, equine hepatocytes, ovine hepatocytes and rodent hepatocytes.
- The invention further concerns the embodiment of such a method in which the preparation comprises a pooled preparation of hepatocytes of multiple sources, which may be of the same or different gender, race, or health state, or which provide the pooled preparation with a desired level of a metabolic activity (especially wherein the metabolic activity is selected from the group consisting of COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, PHEN and CZX).
- The invention also concerns a method of investigating in vitro drug metabolism comprising incubating hepatocytes of a multi-cryopreserved hepatocyte preparation in the presence of a xenobiotic, and determining the metabolic fate of the xenobiotic, or the effect of the xenobiotic on the hepatocytes or on an enzyme or metabolic activity thereof wherein the hepatocytes have been frozen and thawed at least two times, and wherein greater than 50% and more preferably 70% or more of the hepatocytes of the preparation are viable.
- The present invention relates to novel cell compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The methods of the present invention are generally applicable to a wide variety of cell types, including hepatocytes, kidney cells, spleen cells, thymus cells, bone marrow cells, stem cells, muscle cells (including cardiac muscle cells), endocrine cells (including pancreatic cells, adrenal cells, thyroid cells, etc.) epidermal cells, endodermal cells, etc. The methods of the present invention are illustrated below with respect to a preferred cell type: hepatocytes.
- The invention also concerns preparations of cells, e.g., hepatocytes, that have been repeatedly cryopreserved and thawed to obtain a high viability preparation useful for a variety of experimental, diagnostic and therapeutic purposes. The present invention extends the ability of hepatocytes to be cryopreserved and thawed for later use, so as to permit hepatocyte preparations to be repeatedly cryopreserved and thawed without an unacceptable loss of viability.
- As used herein, the term “cell preparation” denotes a liquid or frozen composition of cells from one or more sources (e.g., “hepatocyte preparation”, denotes a composition of liver cells from one or more sources). The sources may be primary cells that have been dissociated from or isolated from tissue as by resection, biopsy, or from donor organs, or they may be secondary, immortalized or transformed cell cultures. The cells may be derived from any mammalian source, including human, porcine, simian, canine, feline, bovine, equine, ovine or rodent sources. The use of human, porcine or rodent (especially rat) cells is preferred. Preferably, greater than 50% and more preferably 70% or more of the hepatocytes of such preparations will be viable.
- As used herein, the term “multi-cryopreserved cell preparation” denotes a cell preparation that has been frozen and then thawed at least two times (e.g., a “multi-cryopreserved hepatocyte preparation” denotes a hepatocyte preparation that has been frozen and then thawed at least two times). Such preparations may have been frozen and thawed three, four, five, or more times.
- The term “pooled preparation” denotes a cell (e.g., hepatocyte) preparation in which the cells (e.g., hepatocytes) are derived from two, three, four, five, or more different sources, such as different donors, biopsies, tissue resections from different tissue samples or different tissue sources, or different primary, secondary, immortalized or transformed cell (e.g., hepatocyte) cultures. The cells of such pooled preparations may be randomly selected cell, or may have been selected to provide the pooled preparation with a desired level of one or more metabolic activities (such as for example, a preparation of hepatocytes having a desired level of COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, PHEN and/or CZX activity), or a desired cell characteristic (such as, for example, a preparation of hepatocytes derived from sources of the same gender, age, race (e.g., Caucasian, etc.), or health state (e.g., hepatocytes of hepatitis virus-infected liver, hepatocytes of HIV-1 infected liver, hepatocytes of healthy liver, hepatocytes of cigarette smokers, hepatocytes of individuals suffering from cirrhosis of the liver, or from other diseases or conditions). For example, to obtain a pooled hepatocyte preparation with minimal DEX activity, a pooled preparation could be prepared from Lot. Nos. 067, CEK, ETR, PFM, VTA, or WWM (see, Table III).
- In a preferred embodiment, illustrated with respect to hepatocyte cells, the practice of the invention comprises some or all of the following steps: the isolation of hepatocytes, a first cryopreservation of the isolated primary hepatocytes to obtain a first cryopreserved hepatocyte preparation, the thawing of the first cryopreserved hepatocyte preparation to obtain viable hepatocytes, and the reformulation of the thawed viable hepatocytes to permit their further storage and use through repeated cryopreservation and thawing to obtain viable hepatocytes.
- Any of a wide variety of methods may be employed or adapted to permit the isolation of the primary hepatocytes used in the present invention. For 30 example, suitable techniques for the isolation of hepatocytes are outlined in Morsiani et al, (1995) “Automated Liver Cell Processing Facilitates Large Scale Isolation And Purification Of Porcine Hepatocytes,” ASAIO Journal 41:155-161 and in Seglen, P. O. (1976) “Preparation Of Isolated Rat Liver Cells,” Meth. Cell Biol. 13:29-83). Specific reference is made to the two-step collagenase digestion procedure described in Li, A. P. et al. (1992) “Isolation And Culturing Of Hepatocytes From Human Liver,” J. Tissue Cult. Meth. 14:139-146.
- The hepatocytes may be cultured in any suitable hepatocyte culture medium. By way of illustration and not limitation mention may be made of the following culture media Chee's Essential Media (Hamilton, G. A. et al. (2001) “Effects Of Medium Composition On The Morphology And Function Of Rat Hepatocytes Cultured As Spheroids And Monolayers,” In Vitro Cell Dev Biol Anim. 37(10):656-667; Zurlo, J. et al. (1996) “Characterization Of A Primary Hepatocyte Culture System For Toxicological Studies,” In Vitro Cell Dev Biol Anim. 32(4):211-220; Arterburn, L. M. et al. (1995) “A Morphological Study Of Differentiated Hepatocytes In Vitro,” Hepatology 22(1):175-187), Modified Eagle Medium (or Dulbecco's Modified Eagle Medium) (Arikura, J. et al. (2002) “UW Solution: A Promising Tool For Cryopreservation Of Primarily Isolated Rat Hepatocytes,” J Hepatobiliary Pancreat Surg. 9(6):742-749; Washizu, J. et al. (2000) “Amino Acid Supplementation Improves Cell-Specific Functions Of The Rat Hepatocytes Exposed To Human Plasma,” Tissue Eng. 6(5):497-504; Iwata, H. et al. (1999) “In Vitro Evaluation Of Metabolic Functions Of A Bioartificial Liver,” ASAID J. 45(4):299-306; Stutenkemper, R et al. (1992) “The Hepatocyte-Specific Phenotype Of Murine Liver Cells Correlates With High Expression Of Connexin32 And Connexin26 But Very Low Expression Of Connexin43,” Exp Cell Res. 201(1):43-54), Leibowitz medium (Coundouris, J. A. et al. (1993) “Cryopreservation Of Human Adult Hepatocytes For Use In Drug Metabolism And Toxicity Studies,” Xenobiotics: 23(12):1399-1409), Waymouth (Vind, C. et al. (1992) “Regulation By Growth Hormone And Glucocorticoid Of Testosterone Metabolism In Long-Term Cultures Of Hepatocytes From Male And Female Rats,” Biochem Pharmacol. 44(8):1523-1528; Nemoto, N. et al. (1991) “Proline Is Required For Transcriptional Control Of The Aromatic Hydrocarbon Inducible P(1) 450 Gene In C57BL16 Mouse Monolayer-Cultured Hepatocytes,” Jpn J Cancer Res. 82(8):901-908; Dich, J. et al. (1988) “Long-Term Culture Of Hepatocytes: Effect Of Hormones On Enzyme Activities And Metabolic Capacity,” Hepatology. 8(1):39-45; Goethals, F. et al. (1984) “Critical Biochemical Functions Of Isolated Hepatocytes As Sensitive Indicators Of Chemical Toxicity,” Fundam Appl Toxicol. 4 (3 Pt 1):441-450), Kreb's medium (House, J. D. (2001) “Threonine Metabolism In Isolated Rat Hepatocytes,” Am J Physiol Endocrinol Metab. 281(6):E1300-1307; Irvine, F. et al. (1993) “Extracellular Calcium Modulates Insulin's Action On Enzymes Controlling Cyclic AMP Metabolism In Intact Hepatocytes,” Biochem J. 293 (Pt 1):249-253; Marsh, D. C. et al. (1991) “Hypothermic Preservation Of Hepatocytes. III. Effects Of Resuspension Media On Viability After Up To 7 Days Of Storage,” Hepatology 13(3):500-508), etc.
- In a preferred embodiment, hepatocytes are cryopreserved in a medium containing approximately 10% DMSO and approximately 90% fetal bovine serum (Loretz, L. J. et al. (1989) “Optimization Of Cryopreservation Procedures For Rat And Human Hepatocytes,” Xenobiotics 19:489-498; Ruegg, C. E. et al. (1997) “Cytochrome-P450 Induction and Conjugated Metabolism In Primary Human Hepatocytes After Cryopreservation,” In Vitro Toxicol. 10:217-222).
- The viability of the isolated hepatocytes may be determined using any of a variety or methods. Preferable, such viability will be determined using the Trypan blue exclusion method (see, e.g., Berry, M. N. et al. (1992) “Techniques For Pharmacological And Toxicological Studies With Isolated Hepatocyte Suspensions,” Life Sci. 51(1):I-16). Thus the phrases “viable hepatocytes” or “percent viability”, as used herein, refers to hepatocyte viability as assessed using the method of Trypan Blue exclusion.
- The hepatocytes of the present invention are preferably cryopreserved using liquid nitrogen, and most preferably within 36 hours of their isolation. Considerations for the cryopreservation of human hepatocytes are discussed in Lloyd, T. D. R. et al. (2003) Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking,” Cell and Tissue Culture Banking 4:3-15. Suitable procedures for the cryopreservation of hepatocytes may also be found in the following documents: Adams, R. M. et al. (1995) “Effective Cryopreservation And Long-Term Storage Of Primary Human Hepatocytes With Recovery Of Viability, Differentiation, And Replicative Potential,” Cell Transplant. 4(6):579-586; Chesne, C. et al. (1993) “Viability And Function In Primary Culture Of Adult Hepatocytes From Various Animal Species And Human Beings After Cryopreservation,” Hepatology 18(2):406-414; Coundouris, J. A. et al. (1993) “Cryopreservation Of Human Adult Hepatocytes For Use In Drug Metabolism And Toxicity Studies,” Xenobiotica. 23(12):1399-1409; Hewitt, N. J. et al. (2004) Cryopreserved Rat Dog And Monkey Hepatocytes: Measurement Of Drug Metabolizing Enzymes In Suspensions And Cultures,” Hum Exp Toxicol. 23(6):307-316; Novicki, D. L. et al. (1982) “Cryopreservation Of Isolated Rat Hepatocytes,” In Vitro. 18(4):393-399; Shaddock, J. G. et al. (1993) “Cryopreservation And Long-Term Storage Of Primary Rat Hepatocytes: Effects On Substrate-Specific Cytochrome P450-Dependent Activities And Unscheduled DNA Synthesis,” Cell Biol Toxicol.9(4):345-357; Zaleski, J. et al. (1993) “Preservation Of The Rate And Profile Of Xenobiotic Metabolism In Rat Hepatocytes Stored In Liquid Nitrogen,” Biochem Pharmacol. 46(1):111-116.
- Preferably, isolated hepatocytes are suspended in a cryoprotective medium, and the suspended cells are dispensed into freezer-safe containers. A cryoprotective medium typically comprises a hepatocyte culture medium that contains at least one cryoprotectant that minimizes the deleterious effects of cryopreservation such as the formation of intracellular ice during freezing. By way of illustration and not limitation, the following commonly used cryoprotectants are listed: dimethylsulfoxide (DMSD), polyethylene glycol, amino acids, propanediol, and glycerol. A preferred cryoprotectant of the present invention is DMSD. Suitable cryoprotectants and methods for their use in hepatocyte cryopreservation can be found, for example, in: Lore, L. J. et al. (1989) “Optimization Of Cryopreservation Procedures For Rat And Human Hepatocytes,” Xenobiotica. 19(5):489-498; Chesne, C. et al. (1993) “Viability And Function In Primary Culture Of Adult Hepatocytes From Various Animal Species And Human Beings After Cryopreservation,” Hepatology 18(2):406-414; Diener, B. et al. (1993) “A Method For The Cryopreservation Of Liver Parenchymal Cells For Studies Of Xenobiotics,” Cryobiology 30(2):116-127; Lawrence, J. N. et al. (1991) “Development Of An Optimal Method For The Cryopreservation Of Hepatocytes And Their Subsequent Monolayer Culture. Toxicology In Vitro,” 5(1):39-51; Houle, R. et al. (2003) “Retention of Transporter Activities in Cryopreserved, Isolated Rat Hepatocytes,” Drug Metab. Disposit. 31(4):447-451; Silva, J. M. et al. (1999) “Induction Of Cytochrome-P450 In Cryopreserved Rat And Human Hepatocytes,” Chem-Biol Interact 121:49-63.
- The isolated hepatocytes are preferably suspended in a cryoprotective medium in preparation for freezing. The suspended cells are preferably dispensed into freezer resistant containers at a cell density of from about 105 cells/ml to about 4×10′ cells/ml. Preferred freezing volumes range from 0.1-10.0 ml. The preferred freezing volume is 1.0 ml.
- The dispensed hepatocytes are then preferably cryopreserved using a controlled rate freezing process, most preferably at a freezing rate of between about −1° C./min to about −25° C./min until a final temperature of about −90° C. is reached. During the initial phase of the cryopreservation process, seeding may be employed to induce controlled crystallization or ice formation in cell suspensions that have already been cooled to below the freezing point of the culture medium. Such seeding serves to minimize ice formation-related damage and therefore may be beneficial to cell viability. Suitable seeding methods include inserting a cold metal rod into the freezing containers, and introducing a blast of liquid nitrogen into the freezing containers.
- Once the desired final temperature has been reached, the frozen cell samples may be transferred to liquid nitrogen freezers for prolonged storage. The frozen samples may be stored in either the liquid nitrogen phase or the gas phase of liquid nitrogen. Preferably storage is accomplished in the gas phase of liquid nitrogen. The frozen samples may be stored in this manner for days, months, or years, with the length of storage in the gas phase of liquid nitrogen having little effect on the post-thaw viability and function.
- Frozen samples may be thawed for further processing by removing them from the presence of liquid nitrogen or liquid nitrogen vapor. Frozen samples are preferably thawed by placing the samples immediately into a prewarmed water bath having a temperature of between about 37° C. to about 42° C. Preferably, cells are thawed to at least the stage in which ice chunks can be dislodged when the sample container is inverted. The thawed cells are then preferably rapidly processed to remove the cells from contact with DMSO, for example by PERCOLL® (colloidal silica particles of 15-30 nm diameter (23% w/w in water) which have been coated with polyvinylpyrrolidone (PVP)) gradient centrifugation (as described below) or by sequential washings.
- In a preferred embodiment, the cells are thawed into Complete INVITROGRO™ CP medium (In Vitro Technologies, Baltimore, Md.; Roymans. U. et al. (2004) “Determination Of Cytochrome P450 IA2 And Cytochrome P4503a4 Induction In Cryopreserved Human Hepatocytes,” Biochem. Pharmacol. 67(3):427-437) (hepatocyte plating medium, which contains water, Dulbecco's Modified Eagle Medium, sodium bicarbonate, HEPES, fructose, bovine serum albumin, sodium hydroxide, MEM non-essential amino acids, insulin, hydrocortisone, and newborn calf serum). The medium is prepared by thawing TORPEDO™ Antibiotic Mix (In Vitro Technologies, Baltimore, Md.) (a mixture of antibiotics selected to inhibit bacterial growth in hepatocyte cell cultures that contains penicillin, streptomycin, gentamicin, amikacin and fungizone) to 37° C. in a water bath until thawed, and then removed from the water bath. 1.0 ml of TORPEDO™ Antibiotic Mix is then mixed with 45 ml INVITROGRO™ CP medium. Following the addition of TORPEDO™ Antibiotic Mix, the shelf life for the complete medium is 7 days. When thawing a single vial, the INVITROGRO™ CP medium is prewarmed to approximately 37° C. 5 ml of warmed INVITROGRO™ CP medium is added to a sterile 50 ml conical tube. The vial of frozen hepatocytes is carefully removed from the freezer. If the vial was stored in the liquid phase, its cap is carefully removed, any liquid nitrogen present in the vial is decanted, and the cap is reclosed before placing the vial into the water bath. It is preferred to then immediately immerse the vial into a 37° C. water bath, and to shake the vial gently until the ice is entirely melted, but no longer than it takes to completely thaw the vial. It may be helpful to remove any labels from the vial so that it will be easier to view the vial contents. The thawed contents are then emptied into the pre-warmed INVITROGRO™ CP medium. 1.0 ml of pre-warmed INVITROGRO™ CP medium then is added to each vial to resuspend any remaining cells. The contents of the vial are then decanted or pipetted into the hepatocyte suspension. The hepatocytes are preferably resuspended by gently inverting the receiving container (e.g., vial, test rube, etc.) several (e.g., three) times.
- When thawing multiple vials, it is preferred that all of the vials be thawed in the water bath simultaneously. As before, the medium (preferably, INVITROGRO™ CP medium) should be warmed to 37° C. It is desirable to ensure that there is enough medium to permit 5 ml of pre-warmed INVITROGRO™ CP medium to he used for each vial of cryopreserved hepatocytes. After vials have thawed, their caps should be quickly removed and their contents poured into a sterile tube or beaker that contains at least 5 ml of pre-warmed INVITROGRO™ CP medium per vial thawed. For example, 25 ml of media is preferably employed for 5 vials in a container that can hold a volume of 50 ml.
- If desired, the total cell count and the number of viable cells may be determined using the Trypan Blue exclusion method. Cells may he diluted to 0.70×106 viable cells/ml with INVITROGRO™ CP medium.
- One aspect of the present invention concerns the ability to reformulate the thawed cells so that they may be refrozen and rethawed on one or more subsequent occasions. Such multi-cryopreserved hepatocyte preparations have multiple uses. They may be used in bioartificial livers, liver cell transplants, liver assist devices, hepatocyte transplantations, and in vitro applications. In particular, multi-cryopreserved hepatocyte preparations may be used in in vitro drug metabolism studies (for example, in identifying hepatocytes with unique characteristics (e.g., metabolic polymorphisms, genetic polymorphisms, etc.), in studies on the metabolic fate of the xenobiotic and studies on the affect of the xenobiotic in altering the drug-metabolizing enzyme profile of the hepatocytes, in inhibition studies to determine the IC50 of xenobiotics on liver enzymes and functions (e.g. cholesterol metabolism), in gene induction studies with xenobiotics, in protein induction studies with xenobiotics, in toxicity assessment of xenobiotics on hepatocytes, transport studies with xenobiotics (e.g. studies on P-glycoprotein transport systems, organic ion transporters, organic cation transporters, etc.), in metabolic clearance studies with xenobiotics, and in efficacy assays (e.g. lipoprotein processing, gluconeogenesis, protein secretion etc.). Multi-cryopreserved hepatocyte preparations may also be used to study or propagate hepatitis viruses and other infectious viruses and agents. Recovered cells may be reformulated for use in DNA, mRNA or proteomic studies or in studies of metabolic polymorphisms. Multi-cryopreserved hepatocyte preparations may also be used in metabolic clearance studies and efficacy assays (e.g., lipoprotein processing, gluconeogenesis, protein secretion, etc.). Cells may be reformulated for use in seeding bioreactors for large scale incubations or as models for gene regulation via micro RNA, or for use in combination systems with other cell types (e.g. non-parenchymal cells from liver or cells from other sources, e.g. Caco-2 cells).
- In a preferred embodiment of the invention, such reformulation comprises separating viable and non-viable cells prior to a subsequent refreezing. Density gradient centrifugation is preferably employed for this purpose. For example, a 30% PERCOLL® gradient centrifugation procedure may be employed (Madan. A. et al. (1999) “Effect of Cryopreservation on Cytochrome P-450 Enzyme Induction in Cultured Rat Hepatocytes, Drug Metab. Dispos. 27(3):327-335; Sun, E. L. et al. (1990) “Cryopreservation Of Cynomologus Monkey (Macaca fascicularis) Hepatocytes For Subsequent Culture And Protein Synthesis Studies,” In Vitro Cell Development and Biology 25:147-150; Lawrence, J. N. et al. (1991) “Development Of An Optimal Method For The Cryopreservation Of Hepatocytes And Their Subsequent Monolayer Culture,” Toxicology In Vitro, 5(1):39-51; Dou, M. et al. (1992) “Thawed Human Hepatocytes In Primary Culture,” Cryobiology 29(4):454-469; Utesch, D. et al. (1992) “Characterization Of Cryopreserved Rat Liver Parenchymal Cells By Metabolism Of Diagnostic Substrates And Activities Of Related Enzymes,” Biochemical Pharmacology 44:309-315). For example, the thawed cells may be resuspended in a prewarmed (approximately 37° C.) 30% PERCOLL® isotonic fractionation buffer and then centrifuged at 100×g at room temperature for twenty minutes to pellet viable cells. The supernatant is discarded and the cells are resuspended in media for a subsequent cryopreservation step directly or for further processing prior to cryopreservation.
- Cryopreserved preparations that result from the freezing of a previously frozen-thawed preparation will preferably have a post-thaw cell viability of greater than 50% and more preferably 70% or more. Such high viabilities enable the present invention to accomplish the repeated freezing and thawing of hepatocytes without unacceptable losses of cells or the need for ever greater samples sources.
- The capacity of the present invention to enable the repeated freezing and thawing of hepatocytes additionally facilitates the production of pooled hepatocyte preparations, especially pooled human hepatocyte preparations. As discussed above, individual liver samples yield hepatocytes having differing metabolic capabilities. In order to facilitate the reproducible use or study of hepatocytes, it is desirable to minimize hepatocyte differences attributable to such sample variation by pooling hepatocytes from different sources to obtain a composite or “average” hepatocyte preparation. Such composite hepatocyte preparations may thus be formulated so as to provide a preparation having the metabolic activities of an “average” hepatocyte sample or a preparation whose hepatocyte enzyme functions approximate the hepatocyte enzyme functions of freshly isolated hepatocytes. Such metabolic activities may include, for example, some or all of the following enzymatic activities: coumarin 7-hydroxylase (COUM), dextromethorphan O-demethylase (DEX), 7-ethoxycoumarin O-deethylase (ECOD), activities responsible for the phase II metabolism of 7-hydroxycoumarin (7-HCG and 7-HCS), mephenyloin 4-hydroxylase (MEPH), testosterone 6(B)-hydroxylase (TEST), tolbutamide 4-hydroxylase (TOLB), phenacetin O-deethylase (PHEN), or chlorzoxazone 6-hydroxylase (CZX). The substrates, methods of measurements and assay units for assays of such metabolic activities are provided in Table 1.
-
TABLE I Hepatocyte Metabolic Activities Abbreviation Substrate/Assay Method of Measurement Units 7-HCG 7- Phase II metabolism of 7- Pmol/min/106 cells hydroxycoumarin hydroxycoumarin glucuronide 7-HCS 7- Phase II metabolism Pmol/min/106 culls hydroxycoumarin of 7-hydroxycoumarin sulfate NAT1 p-aminobenzoic acid N-acetylation of p- nmol/mg/min aminobenzoic acid NAT2 Sulfamethazine N-acetylation of nmol/mg/min Sulfamethazine VBTY viability Trypan Blue ™ percentage Exclusion AP Alkaline Phosphatase Sigma kit units/mg protein GGT gamma-glutamyl GGT stain positive transpeptidase UGT1 7-hydroxycoumarin Phase I1 metabolism 169 pmol/mg/min of 7-hydroxycoumarin P450 cytochrome p450 carbon monoxide Not determined for content difference spectrum cryo hepatocytes nmol/mg protein CZX chlorzoxazone chlorzoxazone 6- 31.1 pmol/mg/min* hydroxylation COUM coumarin coumarin 7- 50.0 pmol/mg/min* hydroxylation DEX dextromethorphan dextromethorphan O- 21.4 pmol/mg/min* demethylation MEPH mephenytoin mephenytoin 4- 24.1 pmol/mg/min* hydroxylation PHEN phenacetin phenacetin O- 28.9 pmol/mg/min* deethylation TEST testosterone testosterone 6(beta)- 96.8 pmol/mg/min* hydroxylation TOLB tolbutamide tolbutamide 4- 30.6 pmol/mg/min* hydroxylation PROT protein content Pierce protein kit Not determined for cryo hepatocytes mg/mL ECOD ethoxycoumarin 7-ethoxycoumarin O- 37.3 pmol/mg/min* demethylation - For example, preferred preparations of pooled hepatocytes will yield assay values within the ranges identified in Table II. Alternatively, the hepatocytes samples used to form the pooled preparation may be selected so as to maximize, minimize, or emphasize certain hepatocyte functions over other functions so as to yield a pooled preparation that exhibits a user desired profile of liver cell function(s).
- The pooled hepatocyte preparations of the present invention may comprise hepatocytes obtained from the same source at differing times, or from two or more different sources. Preferably, pooled hepatocyte preparations will result from the pooling of hepatocytes obtained from three, four, five, six or more different sources.
- Most preferably, the pooled hepatocyte preparations of the invention will comprise at least one population of hepatocytes that were cryopreserved prior to pooling. For example, a pooled hepatocyte preparation may comprise one or more hepatocyte specimens that were cryopreserved prior to pooling with one or more freshly isolated hepatocyte specimens. Alternatively, a pooled hepatocyte preparation may comprise only hepatocyte specimens that were previously cryopreserved. Table II provides the normal range (i.e., the range between Assay Minimum and Assay Maximum for each Assay). Table II values are derived data of the last 150+ lots of human cryopreserved hepatocytes.
-
TABLE II Hepatocyte Assays Normal Range Assay (pmol/min/106 cells) coumarin 7-hydroxylation 1 to 154 Dextromethorphan O-demethylation 0.5 to 96 7-ethoxycoumarin O-deethylation 1 to 154 Phase I metabolism of 7-hydroxycoumarin 2 to 545 Phase II metabolism of 7-hydroxycoumarin 0 to 110 mephenytoin 4-hydroxylation 0.2 to 442 testosterone 6(beta)-hydroxylation 2 to 675 tolbutamide 4-hydroxylation 1.8 to 82 phenacetin O-deethylation 1 to 125 chlorzoxazone 6-hydroxylation 2 to 215 - In certain embodiments of the invention, hepatocyte preparations will have assay values in the above stated ranges for at least three of, and preferably for at least four of, still more preferably for at least six of, and most preferably for at least eight of the following assays: the COUM assay; the DEX assay; the ECOD assay; the 7-HCG assay; the 7-HCS assay; the MEPH assay; the TEST assay; the TOLB assay; the PHEN assay; the CZX assay.
- If desired, the cryopreserved hepatocytes may be plated on to collagen-coated tissue culture plates, or tissue culture plates coated with other extracellular matrix proteins including but not limited to laminin, fibronectin, entactin, poly-L-lysine, gelatin, or any combination thereof. Preferably, this is accomplished by diluting an appropriate volume (e.g., 0.2 ml to 2.5 ml) of diluted cells (e.g., cells having a concentration of approximately 0.7×106 cells/ml) onto the plates. For plating on a 96-well microliter plate, it is desirable to further dilute the cell suspension to a concentration of 0.35×106 cells/ml with INVITROGRO™ Medium, and to add 100 μl of the cell suspension to each well. It is preferred to even distribute the cells in the wells. This can be accomplished by gently shaking the plates in a back-and-forth and side-to-side manner; the use of a circular motion will cause the cells to evenly pool in the center of the wells. Human hepatocytes handled in this manner will attach to the plates in 2-4 hours, however, if minimal handling is desired, the cells can be allowed to attach overnight.
- Having now generally described the invention, the same will be more readily understood through reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention unless specified.
- Cryopreserved hepatocytes are thawed and refrozen as indicated below.
- Materials: 30 cc syringe, two couplers, PERCOLL® in a 1 L bag, INVITROGRO™ CP medium in a 2 L bag, 1-2 L autoclaved beaker, heater, waterbath, centrifuge tube rack.
- Procedure:
- 1) Set up a recirculating waterbath heater at 37-42° C.
- 2) Add approximately 200-400 mls of INVITROGRO™ CP medium to a 1-2 L beaker. Equip Biological Safety Cabinet with a manual pipet or a liquid handling robot.
- 3) Remove approximately 50 cryovials from dewar receptacle and quickly place them in 2 test tube racks. When possible, space vials apart.
- 4) Submerge solid cell suspensions into heated waterbath until the ice chunks can be dislodged when the vial is inverted.
- Pour cell suspension from each vial into the beaker. Add 1 ml of INVITROGRO™ CP medium from the small beaker into each vial to rinse and pour contents into the beaker. Transfer thawed cell suspension into a 1 L sterile bag.
- 6) Attach bag, INVITROGRO™ CP medium in a 2 L bag and PERCOLL® bagged at 30% onto COBE® automated cell processor (a centrifugal system incorporating a flexible membrane that allows the removal of fluids while spinning through use of a rotating seal, hydraulic pump and flexible membrane) and process according to standard practices.
- 7) Perform a cell count.
- 8) Cryopreserve cell suspension.
- PERCOLL®/REDIGRAD™ (Amersham Biosciences) is employed for the PERCOLL® density centrifugation. PERCOLL® is composed of colloidal silica coated with polyvinylpyrrolidone (PVP). The REDIGRAD™ formulation is also composed of colloidal silica but is covalently coated with silane. These coatings are thought to render the material non-toxic and ideal for use with biological materials. Both particles have a density of 1.13 g/ml. Centrifugation of samples in the presence of PERCOLL®/REDIGRAD™ results in the spontaneous formation of a density gradient due to the heterogeneity of particle sizes in the medium.
- PERCOLL®/REDIGRAD™ is best used in balanced salt solutions, such as physiological saline (0.15M NaCl), although 0.25 M sucrose may be employed. The addition of 9 parts (v/v) of PERCOLL®/REDIGRAD™ to 1 part (v/v) of either 1.5 M NaCl, 10× concentrated cell culture medium, or 2.5 M sucrose will result in a solution adjusted to about 340 mOs/kg H2O, Solutions of different osmotic pressure can be produced by adjusting the relative volumes of PERCOLL®/REDIGRAD™ and salt or sucrose solution. (Vincent, R. et al. (1984) “Adjustment Of The Osmolality Of Percoll For The Isopycnic Separation Of Cells And Cell Organelles,” Anal. Biochem. 141(2):322-328). The final adjustment to the required osmolality can be carried out by the addition of salts or distilled water. Concentrations other than 10× physiological saline may also be used satisfactorily.
- PERCOLL®/REDIGRAD™ will form self-generated gradients by centrifugation in fixed-angle rotor heads after 15 minutes. Hepatocytes can be separated by centrifugation at 50-100 gav in fixed-angle or swinging bucket rotor heads after 10-30 minutes.
- To illustrate the sample-to-sample variation of different sources of individual (unpooled) hepatocytes, hepatocytes are isolated from 82 different donors and analyzed for cell viability and enzyme function. The following metabolic activities are evaluated: COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, TOLB, PHEN, and CZX. The results are shown in Table III.
-
TABLE III Variation of Hepatocyte Samples 7- 7- Lot No. Sex % V COUM DEX ECOD HCG HCS MEPH TEST TOLB PHEN CZX 067 M 62% 67 1 70 231 24 2 44 35 27 24 086 F 74% 51 23 10 50 9 1 38 13 BQL 18 089 F 77% 25 21 8 23 6 1 11 13 BQL 29 090 F 74% 30 25 7 13 BQL 2 19 15 BQL 16 091 F 73% 13 29 66 44 10 12 252 36 27 36 094 F 67% 41 12 37 24 4 21 126 40 19 87 099 F 86% 21 15 7 4 BQL 1 60 10 BQL 22 104 M 81% 63 21 44 247 25 2 58 37 8 20 105 M 67% 59 15 24 38 14 1 29 27 12 27 110 F 77% 45 24 35 23 4 6 206 11 54 36 111 F 71% 4 10 9 2 3 3 147 2 19 19 114 F 75% 39 23 21 10 5 5 59 TBD 3 45 122 M 79% 26 30 29 80 5 1 42 23 4 25 129 F 90% 4 24 27 67 18 1 16 33 10 51 ACU F 81% 53 8 25 74 18 8 80 16 4 23 AIT F 83% 45 29 13 118 14 BQL 82 15 11 7 AOK M 73% 60 21 58 283 64 5 86 30 24 21 ATR M 73% 7 11 1 39 11 BQL 11 8 3 4 AVF M 70% 59 13 50 210 29 BQL 54 37 11 24 BTP M 88% 66 29 36 214 25 3 50 45 11 12 CEC M 86% 47 26 17 105 27 21 32 57 38 36 CEK F 80% 55 2 39 141 5 16 302 41 7 16 CHD F 77% 30 14 53 471 42 4 28 23 13 26 CPN M 81% 28 6 40 100 13 2 168 14 37 21 ECM M 85% 8 11 10 55 18 6 81 18 21 9 EFA M 69% 9 9 35 47 5 18 66 12 47 67 EHI F 90% 88 3 56 291 45 1 248 21 45 43 EJR F 75% 89 14 32 288 43 8 62 41 1 41 ENR M 73% 69 28 27 124 31 107 77 36 38 32 EOB M 88% 14 11 18 65 9 31 49 14 21 35 ETR F 88% 30 1 34 13 13 7 13 13 37 69 EVY M 80% 2 20 23 218 77 33 24 25 17 38 FNL M 85% 17 27 62 282 32 6 6 50 14 24 FRW M 75% 46 22 16 106 17 48 25 54 44 8 GBE F 77% 5 49 31 165 20 2 16 19 5 54 GNG F 74% 57 17 33 54 8 5 95 22 16 22 GTV F 71% 32 6 8 47 7 BQL 40 28 16 11 GUY M 92% 65 12 11 73 12 20 90 13 5 8 HHG M 83% 2 8 14 251 29 BQL 28 12 4 40 HRU M 90% 43 28 39 175 15 4 69 40 57 44 ICJ M 74% 134 20 60 287 17 BQL 129 82 28 7 IEM M 88% 34 17 23 129 34 72 48 23 19 34 IHR F 76% 17 43 8 84 9 9 95 46 41 7 LID M 86% 36 31 50 307 54 1 142 49 21 51 IRX F 73% 57 5 40 172 24 12 113 43 6 18 JUL M 82% 7 11 3 41 9 7 23 12 2 3 KK5 M 83% 1 8 27 319 38 BQL 61 17 17 42 KPT F 83% 9 12 32 248 30 55 65 26 56 32 KRJ F 76% 6 40 76 359 37 1 11 61 23 20 KRM F 78% 126 36 55 83 17 103 98 46 74 44 K5E M 73% 65 27 52 206 74 21 123 42 93 16 KZO F 82% 38 16 38 262 8 6 75 32 30 20 LAE M 76% 58 15 50 294 22 14 67 63 125 21 MOF F 91% 79 17 29 10 12 2 85 5 7 46 MRS M 72% 119 21 110 450 50 2 675 54 68 28 MTR F 69% 2 33 23 218 3 5 38 67 39 8 MYO F 94% 40 24 9 24 BQL BQL 12 7 BQL 11 NPX F 79% 36 32 13 130 6 15 76 25 20 10 NQT M 85% 76 12 39 80 23 2 151 14 20 34 OAU F 81% 47 26 24 86 8 6 85 46 53 13 OZL M 76% 16 15 61 300 109 3 165 29 17 43 PFM F 87% 21 1 11 67 10 3 116 8 15 33 PXK M 80% 86 35 63 433 78 2 109 62 32 60 QWG F 77% 16 32 29 300 21 9 50 10 BQL 15 REL F 77% 40 20 15 109 9 65 100 33 75 10 RFA F 78% 130 42 49 444 52 6 195 30 28 17 RKB F 95% 42 16 16 100 8 3 36 17 20 19 RML F 76% BQL 6 45 129 31 14 152 24 42 29 RNG F 91% 119 14 97 298 27 177 207 34 71 41 ROE F 82% 73 24 36 302 37 2 55 17 2 51 SEO F 72% 36 25 18 106 9 66 102 50 81 11 SQJ F 74% 115 12 100 285 19 175 210 30 81 42 SRA M 79% 50 6 71 409 84 10 23 28 18 44 TPZ F 83% 120 13 101 301 26 171 204 31 82 41 TSR F 62% 47 66 58 175 20 BQL 6 77 16 34 VCM M 82% 42 28 79 415 110 0.2 94 16 4 215 VEN F 70% 79 69 89 328 53 2 32 58 48 81 VTA M 78% 32 1 25 84 12 5 120 21 40 15 WWM M 84% 42 1 27 127 12 6 58 21 16 37 ZAG M 85% 35 28 39 96 73 1 11 42 17 18 ZCR M 80% 84 11 39 160 22 38 14 57 20 18 ZIJ M 72% 6 33 31 320 29 13 25 34 3 13 BQL (Below Quantization Limit) TBD (To Be Determined) - Cryopreserved pooled lots of hepatocytes are prepared and analyzed for post-thaw viability and enzyme function. The following metabolic activities are evaluated: COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, TOLB, PHEN, and CZX.
- Six lots of pooled hepatocytes, comprising either five-donor pools or ten-donor pools, are prepared as described above. Hepatocytes are harvested from individual donors and then cryopreserved as individual lots using liquid nitrogen as freezing agent. Cryopreservation is accomplished by suspending the hepatocytes into freezer-safe vials containing a medium having approximately 10% DMSD and approximately 90% Cryopreservation Medium. The dispensed hepatocytes are then frozen in a controlled rate freezer until a final temperature of approximately −80° C. is reached.
- To form the pooled hepatocyte preparations, individual lots are thawed, and the viable cells are isolated by PERCOLL® gradient centrifugation. Vials of individual donor cryopreserved hepatocytes were thawed in a 37° C. waterbath (perhaps it would be better to give a range such as 30-40° C. waterbath?) for 60-90 seconds. The thawed cells are decanted into 37° C. media containing 30% Isotonic PERCOLL® and 70% CP-2 media. The cell suspension is centrifuged at 100 g for 20 minutes. The viable cells are recovered in cryopreservation media and counted. The viable cells are diluted to 20 million cells per mL. A second solution containing 20% DMS4 and 80% cryopreservation media (equal volume to the cell suspension listed above) is prepared. The 20% DMSO and 80% cryopreservation media is slowly added to the cells suspension mixture. The addition takes 5-10 minutes. The resulting mixture is 10% DMSO, 90% cryopreservation media with cells at 10 million cells per mL. This solution is aliquoted into cryovials at 1.0 mL per vial. The cells are then cryopreserved. Viable cells from individual lots are then pooled to form pooled hepatocyte preparations whose cells have functional assay values within desired ranges.
- The pooled lots are then cryopreserved. Table IV below shows the results of the post-thaw viability (“% V”) and enzyme function analysis of the pooled lots. As indicated in Table III, pools had an average viability of 79% (S.D. ±6%).
-
TABLE IV Pool % V COUM DEX ECOD 7-HCG 7-HCS MEPH TEST TOLB PHEN CZX MJIa 89 63 28 66 301 44 12 70 61 50 62 YDJa 72 66 30 80 470 41 1 165 31 27 71 APO 79 79 21 55 276 43 2 112 22 26 30 HMBb 76 61 18 70 231 46 3 151 23 20 83 IJUa 75 32 19 35 232 44 2 124 32 11 42 RKSb 81 84 20 73 336 53 2 131 28 23 55 a5-donor lots b10-donor lots - For comparison, Table V below shows summary data for a post-thaw viability and enzyme function analysis of eighty-one individual lots that are cryopreserved (i.e., subjected to one cycle of cryopreservation). This data confirms that the lot-to-lot variability of enzyme function found in individual hepatocyte sources is very high. The data confirms the desirability of employing pooled hepatocyte preparations for providing cryopreserved cells that approximate the enzyme function of “average” hepatocytes for a wide variety of enzymes.
-
TABLE V Summary of Pooled Hepatocyte Lot Data % V COUM DEX ECO 7-HCG 7-HCS MEPH TEST TOLB PHEN CZX Avg 79 37 17 51 276 27 8 35 35 15 19 High 95 134 69 110 471 110 177 675 82 125 215 Low 62 6 1 31 231 24 2 25 34 3 13 - Characterization of the Viability of Pooled Hepatocytes After Thawing
- A common use of for cryopreserved hepatocytes is to thaw the hepatocytes and then incubate them with various xenobiotics. For this purpose, it is preferred that the hepatocytes maintain their viability for at least several hours. To examine the post-thaw viability over time for one lot of pooled cryopreserved hepatocytes, the cells were thawed, aliquoted into the wells of a 12-well plate, and incubated at 37° C. with 5% CO2. The viability of the hepatocytes is then measured at time-points for up to six hours. Table VI shows the results of this analysis, wherein, at six hours, 39% of the hepatocytes remained viable
-
TABLE VI Post-Thaw Viability Analysis of a Pooled Hepatocyte Lot Timepoint % Viabilitya T = 0 88% 0.5 hrs 79% 1.0 hrs 84% 2.0 hrs 79% 3.0 hrs 73% 4.0 hrs 67% 6.0 hrs 69% aviability determined by Trypan Blue - All publications and patents mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
- While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/568,443 US20100075295A1 (en) | 2005-04-21 | 2009-09-28 | Novel Cellular Compositions and Methods for Their Preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/110,879 US7604929B2 (en) | 2005-04-21 | 2005-04-21 | Cellular compositions and methods for their preparation |
US12/568,443 US20100075295A1 (en) | 2005-04-21 | 2009-09-28 | Novel Cellular Compositions and Methods for Their Preparation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/110,879 Continuation US7604929B2 (en) | 2005-04-21 | 2005-04-21 | Cellular compositions and methods for their preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100075295A1 true US20100075295A1 (en) | 2010-03-25 |
Family
ID=35136896
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/110,879 Active 2026-03-05 US7604929B2 (en) | 2005-04-21 | 2005-04-21 | Cellular compositions and methods for their preparation |
US12/568,443 Abandoned US20100075295A1 (en) | 2005-04-21 | 2009-09-28 | Novel Cellular Compositions and Methods for Their Preparation |
US12/568,346 Abandoned US20100075294A1 (en) | 2005-04-21 | 2009-09-28 | Novel Cellular Compositions and Methods for Their Preparation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/110,879 Active 2026-03-05 US7604929B2 (en) | 2005-04-21 | 2005-04-21 | Cellular compositions and methods for their preparation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/568,346 Abandoned US20100075294A1 (en) | 2005-04-21 | 2009-09-28 | Novel Cellular Compositions and Methods for Their Preparation |
Country Status (14)
Country | Link |
---|---|
US (3) | US7604929B2 (en) |
EP (3) | EP2218777A1 (en) |
JP (1) | JP5271076B2 (en) |
CN (2) | CN101501186B (en) |
AU (2) | AU2006240454B2 (en) |
CA (1) | CA2604693C (en) |
DK (2) | DK1891208T3 (en) |
ES (2) | ES2965619T3 (en) |
FI (1) | FI2479259T3 (en) |
HK (1) | HK1113689A1 (en) |
LT (1) | LT2479259T (en) |
PL (1) | PL1891208T3 (en) |
PT (1) | PT1891208E (en) |
WO (1) | WO2006115682A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100075294A1 (en) * | 2005-04-21 | 2010-03-25 | Daniel Dryden | Novel Cellular Compositions and Methods for Their Preparation |
US20130062569A1 (en) * | 2010-05-26 | 2013-03-14 | Xiaoying Mo | Protein-free solution for non-programmed cell cryopreservation |
US8425662B2 (en) | 2010-04-02 | 2013-04-23 | Battelle Memorial Institute | Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies |
WO2018191673A1 (en) * | 2017-04-14 | 2018-10-18 | Children's Hospital Medical Center | Multi donor stem cell compositions and methods of making same |
US10781425B2 (en) | 2010-05-06 | 2020-09-22 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
US11053477B2 (en) | 2014-05-28 | 2021-07-06 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
US11066650B2 (en) | 2016-05-05 | 2021-07-20 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
US11584916B2 (en) | 2014-10-17 | 2023-02-21 | Children's Hospital Medical Center | Method of making in vivo human small intestine organoids from pluripotent stem cells |
US11767515B2 (en) | 2016-12-05 | 2023-09-26 | Children's Hospital Medical Center | Colonic organoids and methods of making and using same |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10611853B1 (en) | 2008-04-01 | 2020-04-07 | Ardent Mills, Llc | Assessing and improving wheat gluten quality with rheometric analysis |
GB0823056D0 (en) * | 2008-12-18 | 2009-01-28 | Ge Healthcare Ltd | Methods for conducting cellular assays |
US20110105359A1 (en) * | 2009-10-30 | 2011-05-05 | Xenotech, Llc | Cryopreservation of cells and subcellular fractions |
US8513015B2 (en) | 2010-06-11 | 2013-08-20 | Corning Incorporated | Laminin-entactin complex and cell culture article and methods thereof |
US20130130374A1 (en) | 2010-08-03 | 2013-05-23 | Life Technologies Corporation | Cellular compositions and methods for their preparation and use |
US9078430B2 (en) * | 2012-09-18 | 2015-07-14 | Albert Li | Cell preparation method |
US20150024406A1 (en) * | 2013-07-17 | 2015-01-22 | Robin N. Coger-Simmons | Increased aquaporin expression on cellular membrane to improve cryopreservation efficiency |
CA2930784C (en) * | 2013-11-22 | 2023-01-31 | Cellectis | Method for generating batches of allogeneic t cells with averaged potency |
CN106659148A (en) * | 2014-05-12 | 2017-05-10 | 鲁斯特生物股份有限公司 | Ready-to-print cells and integrated devices |
US10159244B2 (en) | 2015-02-27 | 2018-12-25 | Lonza Walkersville, Inc. | Method for pooling hepatocytes |
CN108699514B (en) * | 2016-02-26 | 2023-07-07 | 隆萨沃克斯维尔股份有限公司 | Method for pooling hepatocytes |
CN109055305B (en) * | 2018-09-17 | 2021-03-26 | 河南科技大学 | Method for separating and extracting milk cow liver stem cells |
WO2024026313A1 (en) | 2022-07-25 | 2024-02-01 | The Regents Of The University Of California | Methods of producing and using avian embryonic stem cells and avian telencephalic organoids |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795711A (en) * | 1996-04-04 | 1998-08-18 | Circe Biomedical, Inc. | Cryopreserved hepatocytes and high viability and metabolic activity |
US5895745A (en) * | 1996-09-25 | 1999-04-20 | W.R. Grace & Co.-Conn. | Method of thawing cryopreserved cells |
US20020039786A1 (en) * | 2000-01-19 | 2002-04-04 | Reid Lola M. | Liver tissue source |
US20030134418A1 (en) * | 2000-06-01 | 2003-07-17 | Hokkaido Technology Licensing Office Co, Ltd. | Methods of preparing cryopreservable small hepatocytes and methods of cryopreserving the small hepatocytes |
US6759245B1 (en) * | 1999-06-21 | 2004-07-06 | The General Hospital Corporation | Cell culture systems and methods for organ assist devices |
US7604929B2 (en) * | 2005-04-21 | 2009-10-20 | In Vitro Technologies, Inc. | Cellular compositions and methods for their preparation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE165208T1 (en) | 1990-01-17 | 1998-05-15 | Univ California | COMPOSITION FOR IMPROVING THE LIFE SUPPORT OF BIOLOGICAL MATERIALS |
WO2003105663A2 (en) | 2002-06-01 | 2003-12-24 | Stelsys Llc | Liver assist system based on hollow fiber cartridges or rotating bioreactor |
US20040110289A1 (en) | 2002-07-19 | 2004-06-10 | Ludlow John W. | Method for obtaining viable human cells, including hepatic stem/progenitor cells |
US20040265997A1 (en) | 2003-06-27 | 2004-12-30 | Park Sung-Soo | Bio-artificial liver system |
-
2005
- 2005-04-21 US US11/110,879 patent/US7604929B2/en active Active
-
2006
- 2006-03-30 PL PL06739994T patent/PL1891208T3/en unknown
- 2006-03-30 AU AU2006240454A patent/AU2006240454B2/en active Active
- 2006-03-30 CA CA2604693A patent/CA2604693C/en active Active
- 2006-03-30 JP JP2008507685A patent/JP5271076B2/en active Active
- 2006-03-30 WO PCT/US2006/011551 patent/WO2006115682A2/en active Application Filing
- 2006-03-30 PT PT06739994T patent/PT1891208E/en unknown
- 2006-03-30 LT LTEP12159369.3T patent/LT2479259T/en unknown
- 2006-03-30 CN CN2006800183735A patent/CN101501186B/en active Active
- 2006-03-30 EP EP10162905A patent/EP2218777A1/en not_active Withdrawn
- 2006-03-30 EP EP06739994A patent/EP1891208B1/en not_active Revoked
- 2006-03-30 DK DK06739994.9T patent/DK1891208T3/en active
- 2006-03-30 CN CN2013101777183A patent/CN103275924A/en active Pending
- 2006-03-30 EP EP12159369.3A patent/EP2479259B1/en active Active
- 2006-03-30 ES ES12159369T patent/ES2965619T3/en active Active
- 2006-03-30 ES ES06739994T patent/ES2389099T3/en active Active
- 2006-03-30 DK DK12159369.3T patent/DK2479259T3/en active
- 2006-03-30 FI FIEP12159369.3T patent/FI2479259T3/en active
-
2008
- 2008-08-15 HK HK08109087.7A patent/HK1113689A1/en not_active IP Right Cessation
-
2009
- 2009-09-28 US US12/568,443 patent/US20100075295A1/en not_active Abandoned
- 2009-09-28 US US12/568,346 patent/US20100075294A1/en not_active Abandoned
-
2010
- 2010-10-21 AU AU2010235914A patent/AU2010235914A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795711A (en) * | 1996-04-04 | 1998-08-18 | Circe Biomedical, Inc. | Cryopreserved hepatocytes and high viability and metabolic activity |
US6136525A (en) * | 1996-04-04 | 2000-10-24 | Circe Biomedical, Inc. | Method of cryopreserving hepatocytes |
US5895745A (en) * | 1996-09-25 | 1999-04-20 | W.R. Grace & Co.-Conn. | Method of thawing cryopreserved cells |
US6759245B1 (en) * | 1999-06-21 | 2004-07-06 | The General Hospital Corporation | Cell culture systems and methods for organ assist devices |
US20020039786A1 (en) * | 2000-01-19 | 2002-04-04 | Reid Lola M. | Liver tissue source |
US20030134418A1 (en) * | 2000-06-01 | 2003-07-17 | Hokkaido Technology Licensing Office Co, Ltd. | Methods of preparing cryopreservable small hepatocytes and methods of cryopreserving the small hepatocytes |
US7604929B2 (en) * | 2005-04-21 | 2009-10-20 | In Vitro Technologies, Inc. | Cellular compositions and methods for their preparation |
US20100075294A1 (en) * | 2005-04-21 | 2010-03-25 | Daniel Dryden | Novel Cellular Compositions and Methods for Their Preparation |
Non-Patent Citations (1)
Title |
---|
Myhre et al., Transfusion, 1978, 18: 199-203. * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100075294A1 (en) * | 2005-04-21 | 2010-03-25 | Daniel Dryden | Novel Cellular Compositions and Methods for Their Preparation |
US8425662B2 (en) | 2010-04-02 | 2013-04-23 | Battelle Memorial Institute | Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies |
US9115435B2 (en) | 2010-04-02 | 2015-08-25 | Battelle Memorial Institute | Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies |
US10781425B2 (en) | 2010-05-06 | 2020-09-22 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
US20130062569A1 (en) * | 2010-05-26 | 2013-03-14 | Xiaoying Mo | Protein-free solution for non-programmed cell cryopreservation |
US11053477B2 (en) | 2014-05-28 | 2021-07-06 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
US11584916B2 (en) | 2014-10-17 | 2023-02-21 | Children's Hospital Medical Center | Method of making in vivo human small intestine organoids from pluripotent stem cells |
US11066650B2 (en) | 2016-05-05 | 2021-07-20 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
US11767515B2 (en) | 2016-12-05 | 2023-09-26 | Children's Hospital Medical Center | Colonic organoids and methods of making and using same |
WO2018191673A1 (en) * | 2017-04-14 | 2018-10-18 | Children's Hospital Medical Center | Multi donor stem cell compositions and methods of making same |
US20200040309A1 (en) * | 2017-04-14 | 2020-02-06 | Children's Hospital Medical Center | Multi donor stem cell compositions and methods of making same |
Also Published As
Publication number | Publication date |
---|---|
ES2389099T3 (en) | 2012-10-23 |
AU2010235914A1 (en) | 2010-11-11 |
DK1891208T3 (en) | 2012-07-16 |
EP2218777A1 (en) | 2010-08-18 |
CN101501186B (en) | 2013-06-19 |
LT2479259T (en) | 2024-03-12 |
CN103275924A (en) | 2013-09-04 |
CN101501186A (en) | 2009-08-05 |
HK1113689A1 (en) | 2008-10-10 |
EP1891208A2 (en) | 2008-02-27 |
ES2965619T3 (en) | 2024-04-16 |
PT1891208E (en) | 2012-06-20 |
US7604929B2 (en) | 2009-10-20 |
AU2006240454B2 (en) | 2010-07-22 |
JP5271076B2 (en) | 2013-08-21 |
AU2006240454A1 (en) | 2006-11-02 |
CA2604693C (en) | 2012-08-14 |
EP2479259B1 (en) | 2023-11-22 |
EP2479259A2 (en) | 2012-07-25 |
EP1891208B1 (en) | 2012-06-06 |
FI2479259T3 (en) | 2024-02-20 |
WO2006115682A2 (en) | 2006-11-02 |
DK2479259T3 (en) | 2024-02-19 |
WO2006115682A3 (en) | 2009-04-23 |
US20050239042A1 (en) | 2005-10-27 |
CA2604693A1 (en) | 2006-11-02 |
EP2479259A3 (en) | 2012-08-01 |
PL1891208T3 (en) | 2012-11-30 |
JP2008539697A (en) | 2008-11-20 |
US20100075294A1 (en) | 2010-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7604929B2 (en) | Cellular compositions and methods for their preparation | |
US9931360B2 (en) | Isolated liver stem cells | |
Alexandre et al. | Cryopreservation of adult human hepatocytes obtained from resected liver biopsies | |
EP3397753B1 (en) | Microtissue formation using stem cell-derived human hepatocytes | |
WO2005054450A1 (en) | Compositions comprising fetal liver cells and methods useful for hcv infection | |
WO1997016536A1 (en) | Method for ex vivo proliferation and differentiation of adult pancreatic islet cells, media useful therefor and uses thereof | |
WO1992003046A1 (en) | Improved cell cryopreservation method | |
Sugimachi et al. | Long-term function of cryopreserved rat hepatocytes in a coculture system | |
US20150218513A1 (en) | Hepatocyte preparations | |
Talbot et al. | Establishment and characterization of feeder cell-dependent bovine fetal liver cell lines | |
US20150259650A1 (en) | Reliability of assays using a multi-divot platform and multi-source, multi-cell type clusters | |
CN110684717B (en) | Culture system for maintaining function of liver cells in vitro for long term and long-term in vitro culture method of mature liver cells | |
Guillouzo et al. | Storage of isolated hepatocytes | |
WO2018144284A1 (en) | Compositions and methods comprising co-culture of hepatocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CELSIS IN VITRO, INC.,MARYLAND Free format text: CHANGE OF NAME;ASSIGNOR:IN VITRO TECHNOLOGIES, INC.;REEL/FRAME:023720/0785 Effective date: 20100104 Owner name: CELSIS IN VITRO, INC., MARYLAND Free format text: CHANGE OF NAME;ASSIGNOR:IN VITRO TECHNOLOGIES, INC.;REEL/FRAME:023720/0785 Effective date: 20100104 |
|
AS | Assignment |
Owner name: CELSIS IN VITRO INC.,MARYLAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC;REEL/FRAME:023768/0838 Effective date: 20100113 Owner name: CELSIS IN VITRO INC., MARYLAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC;REEL/FRAME:023768/0838 Effective date: 20100113 |
|
AS | Assignment |
Owner name: CELSIS IN VITRO, INC.,MARYLAND Free format text: CHANGE OF NAME;ASSIGNOR:IN VITRO TECHNOLOGIES, INC.;REEL/FRAME:023832/0814 Effective date: 20070424 Owner name: CELSIS IN VITRO, INC., MARYLAND Free format text: CHANGE OF NAME;ASSIGNOR:IN VITRO TECHNOLOGIES, INC.;REEL/FRAME:023832/0814 Effective date: 20070424 |
|
AS | Assignment |
Owner name: KBC BANK NV,UNITED KINGDOM Free format text: SECURITY AGREEMENT;ASSIGNOR:CELSIS IN VITRO, INC.;REEL/FRAME:023854/0652 Effective date: 20100113 Owner name: KBC BANK NV, UNITED KINGDOM Free format text: SECURITY AGREEMENT;ASSIGNOR:CELSIS IN VITRO, INC.;REEL/FRAME:023854/0652 Effective date: 20100113 |
|
AS | Assignment |
Owner name: CELSIS IN VITRO, INC., MARYLAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:KBC BANK NV;REEL/FRAME:029959/0326 Effective date: 20130308 |
|
AS | Assignment |
Owner name: BROWN BROTHERS HARRIMAN & CO., AS ADMINISTRATIVE A Free format text: SECURITY AGREEMENT;ASSIGNOR:CELSIS IN VITRO, INC.;REEL/FRAME:030055/0686 Effective date: 20130313 |
|
AS | Assignment |
Owner name: ABACUS FINANCE GROUP, LLC, AS AGENT, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:CELSIS IN VITRO, INC.;REEL/FRAME:030745/0323 Effective date: 20130628 |
|
AS | Assignment |
Owner name: IN VITRO, INC., MARYLAND Free format text: CHANGE OF NAME;ASSIGNOR:CELSIS IN VITRO, INC.;REEL/FRAME:031723/0322 Effective date: 20130705 |
|
AS | Assignment |
Owner name: GOLUB CAPITAL LLC, AS ADMINISTRATIVE AGENT, ILLINO Free format text: ASSIGNMENT OF SECURITY INTEREST IN PATENTS;ASSIGNOR:ABACUS FINANCE GROUP, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:033106/0921 Effective date: 20140609 |
|
AS | Assignment |
Owner name: CELSIS IN VITRO, INC., MARYLAND Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BROWN BROTHERS HARRIMAN & CO., AS ADMINISTRATIVE AGENT;REEL/FRAME:033217/0051 Effective date: 20130628 |
|
AS | Assignment |
Owner name: GOLUB CAPITAL LLC, AS ADMINISTRATIVE AGENT, ILLINO Free format text: SECURITY INTEREST;ASSIGNOR:IN VITRO, INC.;REEL/FRAME:037408/0099 Effective date: 20160105 |
|
AS | Assignment |
Owner name: IN VITRO, INC., MARYLAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:GOLUB CAPITAL LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:037422/0342 Effective date: 20160105 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |
|
AS | Assignment |
Owner name: IN VITRO, INC., MARYLAND Free format text: RELEASE OF SECURITY INTEREST AT REEL/FRAME NO. 037408/0099;ASSIGNOR:GOLUB CAPITAL LLC;REEL/FRAME:057698/0182 Effective date: 20211001 |